Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
24 "Paclitaxel"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Gastrointestinal cancer
A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer
Ting Liu, Qing Li, Zhen Lin, Chunhua Liu, Wei Pu, Shasha Zeng, Jun Lai, Xuebin Cai, Lisha Zhang, Shuyang Wang, Miao Chen, Wei Cao, Hongfeng Gou, Qing Zhu
Cancer Res Treat. 2024;56(2):602-615.   Published online October 12, 2023
DOI: https://doi.org/10.4143/crt.2023.726
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Patients with advanced biliary tract cancer (BTC) have a poor survival. We aim to evaluate the efficacy and safety of nab-paclitaxel plus gemcitabine and cisplatin regimen in Chinese advanced BTC patients.
Materials and Methods
Eligible patients with locally advanced or metastatic BTC administrated intravenous 100 mg/m2 nab-paclitaxel, 800 mg/m2 gemcitabine, and 25 mg/m2 cisplatin every 3 weeks. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival (OS) and adverse events, while exploratory endpoint was the association of biomarkers with efficacy.
Results
After the median follow-up of 25.0 months, the median PFS and OS of 34 enrolled patients were 7.1 months (95% confidence interval [CI], 5.4 to 13.7) and 16.4 months (95% CI, 10.9 to 23.6), respectively. The most common treatment-related adverse events at ≥ 3 grade were neutropenia (26.5%) and leukopenia (26.5%). Survival analyses demonstrated that carcinoembryonic antigen (CEA) levels could monitor patients’ survival outcomes. A significant increase in the number of infiltrating CD4+ cells (p=0.008) and a decrease in programmed death-1–positive (PD-1+) cells (p=0.032) were observed in the response patients.
Conclusion
In advanced BTC patients, nab-paclitaxel plus gemcitabine and cisplatin regimen showed therapeutic potential. Potential prognostic factors of CEA levels, number of CD4+ cells and PD-1+ cells may help us maximize the efficacy benefit.

Citations

Citations to this article as recorded by  
  • Efficacy and biomarker analysis of second‐line nab‐paclitaxel plus sintilimab in patients with advanced biliary tract cancer
    Xiaofen Li, Nan Zhou, Yu Yang, Zijian Lu, Hongfeng Gou
    Cancer Science.2024; 115(7): 2371.     CrossRef
  • 3,678 View
  • 159 Download
  • 2 Web of Science
  • 1 Crossref
Close layer
Breast cancer
A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer
Jung Sun Kim, Koung Jin Suh, Dae-Won Lee, Go-un Woo, Miso Kim, Se Hyun Kim, Han Suk Ryu, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, So Yeon Park, In Ae Park, Jee Hyun Kim, Seock-Ah Im
Cancer Res Treat. 2022;54(2):488-496.   Published online August 13, 2021
DOI: https://doi.org/10.4143/crt.2021.394
AbstractAbstract PDFPubReaderePub
Purpose
We aimed to assess the real-world efficacy of nab-paclitaxel in metastatic breast cancer patients.
Materials and Methods
This is a retrospective study performed in two tertiary referral hospitals in Korea. Patients with metastatic breast cancer treated with nab-paclitaxel (Abraxane®) between March 2016 and March 2020 were enrolled.
Results
A total of 102 patients with metastatic breast cancer were included. Patients were heavily pre-treated with a median of four prior lines of chemotherapy (5 lines when including endocrine therapy in hormone-receptor-positive patients), and 66 patients (64.7%) were exposed to taxanes in the metastatic setting. According to St. Gallen molecular subtypes, 36 patients (35.3%) were luminal A, 28 (27.5%) were luminal B, 18 (17.7%) were human epidermal growth factor receptor 2–positive and 20 (19.6%) had triple-negative disease. Fifty patients (49.0%) were treated with a 3-weekly regimen (260 mg/m2 on day 1 every 3 weeks), and 52 (51.0%) were treated with a weekly regimen (100 mg/m2 every week). Objective response rate was 22.9%. After a median follow-up of 22.0 months, median progression-free survival (PFS) was 4.0 months (95% confidence interval [CI], 2.6 to 4.8) and median overall survival was 8.7 months (95% CI, 7.5 to 11.2). Patients treated with weekly regimen had longer PFS compared to 3-weekly regimen (5.5 vs. 2.3 months, p < 0.001). Multivariate analysis revealed the treatment regimen as an independent prognostic factor for PFS. There was no grade 3 or 4 hypersensitivity reaction.
Conclusion
This real-world data shows that nab-paclitaxel is a reasonable treatment option in heavily pre-treated and/or taxane-exposed metastatic breast cancer patients.

Citations

Citations to this article as recorded by  
  • Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
    P. Meyer-Wilmes, J. Huober, M. Untch, J.-U. Blohmer, W. Janni, C. Denkert, P. Klare, T. Link, K. Rhiem, C. Bayer, M. Reinisch, V. Bjelic-Radisic, D.M. Zahm, C. Hanusch, C. Solbach, G. Heinrich, A.D. Hartkopf, A. Schneeweiss, P. Fasching, N. Filmann, V. Ne
    ESMO Open.2024; 9(5): 103009.     CrossRef
  • Real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and laboratory parameters in patients across metastatic tumor sites
    Vikas Talreja, Sangeeta Khetwani, Ethirajan Nanadagopal, Nilesh Eknath Borkar, Kunal Khobragade
    International Journal of Molecular and Immuno Oncology.2024; 9: 46.     CrossRef
  • Safety and efficacy of generic nab-paclitaxel-based therapy in Chinese patients with malignant tumors in a real-world setting: a multicenter prospective observational study
    Fei He, Yancai Sun, Wenzhou Zhang, Qiongshi Wu, Donghang Xu, Zaixian Bai, Zhiying Hao, Weiyi Feng, Kanghuai Zhang, Jiang Liu, Mei Dong, Guangxuan Liu, Guohui Li
    Discover Oncology.2024;[Epub]     CrossRef
  • Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study
    Zhichao Tian, Shuping Dong, Yang Yang, Shilei Gao, Yonghao Yang, Jinpo Yang, Peng Zhang, Xin Wang, Weitao Yao
    BMC Cancer.2022;[Epub]     CrossRef
  • Paclitaxel

    Reactions Weekly.2022; 1926(1): 383.     CrossRef
  • Natural Taxanes: From Plant Composition to Human Pharmacology and Toxicity
    Ľuboš Nižnanský, Denisa Osinová, Roman Kuruc, Alexandra Hengerics Szabó, Andrea Szórádová, Marián Masár, Žofia Nižnanská
    International Journal of Molecular Sciences.2022; 23(24): 15619.     CrossRef
  • A Novel Microcrystalline BAY-876 Formulation Achieves Long-Acting Antitumor Activity Against Aerobic Glycolysis and Proliferation of Hepatocellular Carcinoma
    Hua Yang, Mu-Zi-he Zhang, Hui-wei Sun, Yan-tao Chai, Xiaojuan Li, Qiyu Jiang, Jun Hou
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • 7,419 View
  • 223 Download
  • 5 Web of Science
  • 7 Crossref
Close layer
Sarcoma
Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment
Changhee Park, Miso Kim, Yoonjin Kwak, Kyung Chul Moon, Se Hyun Kim, Bhumsuk Keam, Yu Jung Kim, Tae Min Kim, Dong-Wan Kim
Cancer Res Treat. 2021;53(4):1195-1203.   Published online February 1, 2021
DOI: https://doi.org/10.4143/crt.2020.1337
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Angiosarcoma is a highly aggressive mesenchymal tumor. Although systemic chemotherapy is often considered for the inoperable or metastatic angiosarcoma, the outcome of such treatment is unsatisfactory and poorly delineated.
Materials and Methods
We reviewed electronic medical records of 75 patients with angiosarcoma who were treated with systemic chemotherapy for inoperable or metastatic disease. Patients were classified as having liver involvement if they had either primary or metastatic hepatic lesions.
Results
Among the patients evaluated, 51 patients were male (68%) and 24 patients (32%) had primary cutaneous angiosarcoma. Liver involvement was present in 28 patients (37.3%). A total of 59 patients received first-line weekly paclitaxel (wPac) and showed an objective response rate (ORR) of 23.7% (n=14), a median progression free survival (mPFS) of 4.0 months (95% confidence interval [CI] 3.0–6.1), and a median overall survival (mOS) of 10.2 months (95% CI 7.0–14.6). Among patients without liver involvement, patients receiving wPac (n=35) had significantly prolonged mPFS (5.8 vs. 3.2 months, respectively, p=0.014) with a tendency for prolonged mOS (13.8 vs. 11.6 months, respectively, p=0.13) than those receiving other regimens (n=12). A total of 24 patients received second- or later-line pazopanib monotherapy and showed an ORR of 16.7% (n=4), a mPFS of 2.4 months (95% CI 1.8–4.3) and a mOS of 5.4 months (95% CI 3.5–NA).
Conclusion
Treatment with first-line wPac and later-line pazopanib seems to provide survival benefit, especially for patients with advanced angiosarcoma without liver involvement.

Citations

Citations to this article as recorded by  
  • Chest Wall Angiosarcoma with an Initial Presentation of Multiple Lung Metastases: a Case Report
    Hitoshi Suzuki, Mari Shinoda, Daisuke Ito, Shin Shomura, Kentaro Inoue, Kazuo Fukutome, Akira Shimamoto, Hisamichi Yuda
    Haigan.2024; 64(7): 917.     CrossRef
  • Hepatic Angiosarcoma with Peliosis Hepatis
    Kensuke Kitsugi, Kazuhito Kawata, Moe Matsumoto, Masahiro Umemura, Tomohiko Hanaoka, Maho Yamashita, Shingo Takatori, Jun Ito, Kazuyoshi Ohta, Takeshi Chida, Hidenao Noritake, Takafumi Suda
    Internal Medicine.2023; 62(8): 1157.     CrossRef
  • Conversion surgery for recurrent hepatic angiosarcoma after systemic chemotherapy with paclitaxel
    Yuta Ushida, Takafumi Sato, Tomotaka Kato, Yasuyuki Shigematsu, Hiromichi Ito, Takeshi Suzuki, Yosuke Inoue, Yoshihiro Ono, Atsushi Oba, Yu Takahashi
    Clinical Journal of Gastroenterology.2022; 15(2): 427.     CrossRef
  • Management of Cutaneous Angiosarcoma: an Update Review
    Siwei Bi, Ai Zhong, Xiya Yin, Jingyi Li, Ying Cen, Junjie Chen
    Current Treatment Options in Oncology.2022; 23(2): 137.     CrossRef
  • Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with Angiosarcoma
    Richard F Riedel, Victoria Chua, Ania Moradkhani, Natalie Krkyan, Amir Ahari, Atsushi Osada, Sant P Chawla
    The Oncologist.2022; 27(10): 809.     CrossRef
  • 8,536 View
  • 179 Download
  • 4 Web of Science
  • 5 Crossref
Close layer
Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
Kyoungmin Lee, Kyunghye Bang, Changhoon Yoo, Inhwan Hwang, Jae Ho Jeong, Heung-Moon Chang, Dongwook Oh, Tae Jun Song, Do Hyun Park, Sang Soo Lee, Sung Koo Lee, Myung-Hwan Kim, Jin-hong Park, Kyu-pyo Kim, Baek-Yeol Ryoo
Cancer Res Treat. 2020;52(1):254-262.   Published online July 9, 2019
DOI: https://doi.org/10.4143/crt.2019.190
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Since the introduction of nab-paclitaxel plus gemcitabine (nab-P+GEM) as first-line (1L) treatment for metastatic pancreatic adenocarcinoma (mPDAC), optimal second-line (2L) chemotherapy after progression is unclear. We assessed clinical outcomes of 2L chemotherapy for disease that progressed on 1L nab-P+GEM.
Materials and Methods
Among the 203 patients previously treated with 1L nab-P+GEM for mPDAC at Asan Medical Center, between February and December 2016, records of 120 patients receiving 2L chemotherapy after progression on nab-P+GEM were retrospectively reviewed. The response rate and survival were evaluated along with analysis of prognostic factors.
Results
Fluoropyrimidine-oxaliplatin doublets (FOLFOX or XELOX) were used in 78 patients (65.0%), fluoropyrimidine monotherapy in 37 (30.8%), and liposomal irinotecan plus fluorouracil in two (1.7%). The median progression-free survival (PFS) and overall survival (OS) were 3.29 months and 7.33 months from the start of 2L therapy. Fluoropyrimidine-oxaliplatin regimens and fluoropyrimidine monotherapy did not yield significantly different median PFS (2.89 months vs. 3.81 months, p=0.40) or OS (7.04 months vs. 7.43 months, p=0.86). A high neutrophil-lymphocyte ratio (> 2.2) and a short time to progression with 1L nab-P+GEM (< 6.4 months) were independent prognostic factors of poor OS with 2L therapy.
Conclusion
2L fluoropyrimidine-oxaliplatin doublets and fluoropyrimidine monotherapy after failure of 1L nab-P+GEM had modest efficacy, with no differences in treatment outcomes between them. Further investigation is warranted for the optimal 2L chemo-regimens and sequencing of systemic chemotherapy for patients with mPDAC.

Citations

Citations to this article as recorded by  
  • Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma
    Brandon M. Huffman, Atrayee Basu Mallick, Nora K. Horick, Andrea Wang-Gillam, Peter Joel Hosein, Michael A. Morse, Muhammad Shaalan Beg, Janet E. Murphy, Sharon Mavroukakis, Anjum Zaki, Benjamin L. Schlechter, Hanna Sanoff, Christopher Manz, Brian M. Wolp
    JAMA Network Open.2023; 6(1): e2249720.     CrossRef
  • Trend Analysis and Prediction of Hepatobiliary Pancreatic Cancer Incidence and Mortality in Korea
    Hyeong Min Park, Young-Joo Won, Mee Joo Kang, Sang-Jae Park, Sun-Whe Kim, Kyu-Won Jung, Sung-Sik Han
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • EUS-guided ablation with the HybridTherm Probe as second-line treatment in patients with locally advanced pancreatic ductal adenocarcinoma: A case–control study
    Sabrina Gloria Giulia Testoni, Maria Chiara Petrone, Michele Reni, Clelia Di Serio, Paola Maria Rancoita, Gemma Rossi, Gianpaolo Balzano, Walter Linzenbold, Markus Enderle, Emanuel Della-Torre, Francesco De Cobelli, Massimo Falconi, Gabriele Capurso, Paol
    Endoscopic Ultrasound.2022; 11(5): 383.     CrossRef
  • Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
    Jaime Feliu, Mónica Jorge Fernández, Teresa Macarulla, Bartomeu Massuti, Ana Albero, José Federico González González, Guillermo Quintero-Aldana, Juan Ignacio Delgado-Mingorance, Ana Fernández Montes, Carmen García Piernavieja, Manuel Valladares-Ayerbes, A
    Cancer Chemotherapy and Pharmacology.2021; 87(4): 543.     CrossRef
  • Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)
    H.S. Park, B. Kang, H.J. Chon, H.-S. Im, C.-K. Lee, I. Kim, M.J. Kang, J.E. Hwang, W.K. Bae, J. Cheon, J.O. Park, J.Y. Hong, J.H. Kang, J.H. Kim, S.H. Lim, J.W. Kim, J.-W. Kim, C. Yoo, H.J. Choi
    ESMO Open.2021; 6(2): 100049.     CrossRef
  • Pancreatic adenocarcinoma: Beyond first line, where are we?
    Sara Cherri, Silvia Noventa, Alberto Zaniboni
    World Journal of Gastroenterology.2021; 27(17): 1847.     CrossRef
  • Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma
    Mandana Kamgar, Sakti Chakrabarti, Aditya Shreenivas, Ben George
    Surgical Oncology Clinics of North America.2021; 30(4): 673.     CrossRef
  • Treatment optimization of locally advanced and metastatic pancreatic cancer (Review)
    Anabela Barros, Catarina Pulido, Manuela Machado, Maria Brito, Nuno Couto, Olga Sousa, Sónia Melo, Hélder Mansinho
    International Journal of Oncology.2021;[Epub]     CrossRef
  • Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer
    Emma Gränsmark, Nellie Bågenholm Bylin, Hakon Blomstrand, Mats Fredrikson, Elisabeth Åvall-Lundqvist, Nils O. Elander
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules
    Francesca Foschini, Fabiana Napolitano, Alberto Servetto, Roberta Marciano, Eleonora Mozzillo, Anna Chiara Carratù, Antonio Santaniello, Pietro De Placido, Priscilla Cascetta, Giovanni Butturini, Isabella Frigerio, Paolo Regi, Nicola Silvestris, Sabina De
    Therapeutic Advances in Medical Oncology.2020;[Epub]     CrossRef
  • Laparoscopic repeated pancreatectomy for isolated local recurrence in remnant pancreas following laparoscopic radical pancreatectomy for pancreatic ductal adenocarcinoma: Two cases report
    Munseok Choi, Suk Jun Lee, Dong-Min Shin, Ho Kyoung Hwang, Woo Jung Lee, Chang Moo Kang
    Annals of Hepato-Biliary-Pancreatic Surgery.2020; 24(4): 542.     CrossRef
  • Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer
    L. I. Moskvicheva, L. V. Bolotina
    Research and Practical Medicine Journal.2020; 7(4): 118.     CrossRef
  • 9,075 View
  • 314 Download
  • 10 Web of Science
  • 12 Crossref
Close layer
Prediction of Acquired Taxane Resistance Using a Personalized Pathway-Based Machine Learning Method
Young Rae Kim, Dongha Kim, Sung Young Kim
Cancer Res Treat. 2019;51(2):672-684.   Published online August 10, 2018
DOI: https://doi.org/10.4143/crt.2018.137
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study was conducted to develop and validate an individualized prediction model for automated detection of acquired taxane resistance (ATR).
Materials and Methods
Penalized regression, combinedwith an individualized pathway score algorithm,was applied to construct a predictive model using publically available genomic cohorts of ATR and intrinsic taxane resistance (ITR). To develop a model with enhanced generalizability, we merged multiple ATR studies then updated the learning parameter via robust cross-study validation.
Results
For internal cross-study validation, the ATR model produced a perfect performance with an overall area under the receiver operating curve (AUROC) of 1.000 with an area under the precision-recall curve (AUPRC) of 1.000, a Brier score of 0.007, a sensitivity and a specificity of 100%. The model showed an excellent performance on two independent blind ATR cohorts (overall AUROC of 0.940, AUPRC of 0.940, a Brier score of 0.127). When we applied our algorithm to two large-scale pharmacogenomic resources for ITR, the Cancer Genome Project (CGP) and the Cancer Cell Line Encyclopedia (CCLE), an overall ITR cross-study AUROC was 0.70, which is a far better accuracy than an almost random level reported by previous studies. Furthermore, this model had a high transferability on blind ATR cohorts with an AUROC of 0.69, suggesting that general predictive features may be at work across both ITR and ATR.
Conclusion
We successfully constructed a multi-study–derived personalized prediction model for ATR with excellent accuracy, generalizability, and transferability.

Citations

Citations to this article as recorded by  
  • The impact and future of artificial intelligence in medical genetics and molecular medicine: an ongoing revolution
    Firat Ozcelik, Mehmet Sait Dundar, A. Baki Yildirim, Gary Henehan, Oscar Vicente, José A. Sánchez-Alcázar, Nuriye Gokce, Duygu T. Yildirim, Nurdeniz Nalbant Bingol, Dijana Plaseska Karanfilska, Matteo Bertelli, Lejla Pojskic, Mehmet Ercan, Miklos Kellerma
    Functional & Integrative Genomics.2024;[Epub]     CrossRef
  • Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer
    Beatriz Bueschbell, Ana Beatriz Caniceiro, Pedro M.S. Suzano, Miguel Machuqueiro, Nícia Rosário-Ferreira, Irina S. Moreira
    Drug Resistance Updates.2022; 60: 100811.     CrossRef
  • Multiparametric quantitative phase imaging for real-time, single cell, drug screening in breast cancer
    Edward R. Polanco, Tarek E. Moustafa, Andrew Butterfield, Sandra D. Scherer, Emilio Cortes-Sanchez, Tyler Bodily, Benjamin T. Spike, Bryan E. Welm, Philip S. Bernard, Thomas A. Zangle
    Communications Biology.2022;[Epub]     CrossRef
  • Machine Learning: An Overview and Applications in Pharmacogenetics
    Giovanna Cilluffo, Salvatore Fasola, Giuliana Ferrante, Velia Malizia, Laura Montalbano, Stefania La Grutta
    Genes.2021; 12(10): 1511.     CrossRef
  • Computational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets and drug-target interactions
    A. Tolios, J. De Las Rivas, E. Hovig, P. Trouillas, A. Scorilas, T. Mohr
    Drug Resistance Updates.2020; 48: 100662.     CrossRef
  • FLOating-Window Projective Separator (FloWPS): A Data Trimming Tool for Support Vector Machines (SVM) to Improve Robustness of the Classifier
    Victor Tkachev, Maxim Sorokin, Artem Mescheryakov, Alexander Simonov, Andrew Garazha, Anton Buzdin, Ilya Muchnik, Nicolas Borisov
    Frontiers in Genetics.2019;[Epub]     CrossRef
  • New Paradigm of Machine Learning (ML) in Personalized Oncology: Data Trimming for Squeezing More Biomarkers From Clinical Datasets
    Nicolas Borisov, Anton Buzdin
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • 9,147 View
  • 164 Download
  • 6 Web of Science
  • 7 Crossref
Close layer
An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer
In Hae Park, Joo Hyuk Sohn, Sung Bae Kim, Keun Seok Lee, Joo Seop Chung, Soo Hyeon Lee, Tae You Kim, Kyung Hae Jung, Eun Kyung Cho, Yang Soo Kim, Hong Suk Song, Jae Hong Seo, Hun Mo Ryoo, Sun Ah Lee, So Young Yoon, Chul Soo Kim, Yong Tai Kim, Si Young Kim, Mi Ryung Jin, Jungsil Ro
Cancer Res Treat. 2017;49(3):569-577.   Published online September 12, 2016
DOI: https://doi.org/10.4143/crt.2016.289
AbstractAbstract PDFPubReaderePub
Purpose
Genexol-PM is a Cremophor EL–free formulation of low-molecular-weight, non-toxic, and biodegradable polymeric micelle-bound paclitaxel. We conducted a phase III study comparing the clinical efficacy and toxicity of Genexol-PM with conventional paclitaxel (Genexol).
Materials and Methods
Patients were randomly assigned (1:1) to receive Genexol-PM 260 mg/m2 or Genexol 175 mg/m2 intravenously every 3 weeks. The primary outcome was the objective response rate (ORR).
Results
The study enrolled 212 patients, of whom 105 were allocated to receive Genexol-PM. The mean received dose intensity of Genexol-PM was 246.8±21.3 mg/m2 (95.0%), and that of Genexol was 168.3±10.6 mg/m2 (96.2%). After a median follow-up of 24.5 months (range, 0.0 to 48.7 months), the ORR of Genexol-PM was 39.1% (95% confidence interval [CI], 31.2 to 46.9) and the ORR of Genexol was 24.3% (95% CI, 17.5 to 31.1) (pnon-inferiority=0.021, psuperiority=0.016). The two groups did not differ significantly in overall survival (28.8 months for Genexol-PM vs. 23.8 months for Genexol; p=0.52) or progression-free survival (8.0 months for Genexol-PM vs. 6.7 months for Genexol; p=0.26). In both groups, the most common toxicities were neutropenia, with 68.6% occurrence in the Genexol-PM group versus 40.2% in the Genexol group (p < 0.01). The incidences of peripheral neuropathy of greater than grade 2 did not differ significantly between study treatments.
Conclusion
Compared with standard paclitaxel, Genexol-PM demonstrated non-inferior and even superior clinical efficacy with a manageable safety profile in patients with metastatic breast cancer.

Citations

Citations to this article as recorded by  
  • Revolutionizing cancer treatment: ROS-induced apoptosis via nanoformulated alkaloids
    Swathi Putta, Santhosh Kumar Chinnaiyan, Ramadevi Korni, Venkata Radha Gadela
    Journal of Drug Delivery Science and Technology.2025; 104: 106556.     CrossRef
  • Administration of Inhibitory Molecules through Nanoparticles in Breast Cancer Therapy
    Christian Rafael Quijia, Andreina Quevedo Enríquez, Carlos Daniel Zappia, Roxana Noemí Peroni, Marlus Chorilli
    Current Medicinal Chemistry.2024; 31(6): 726.     CrossRef
  • Innovative strategies for effective paclitaxel delivery: Recent developments and prospects
    Sławomir Wileński, Agnieszka Koper, Paulina Śledzińska, Marek Bebyn, Krzysztof Koper
    Journal of Oncology Pharmacy Practice.2024; 30(2): 367.     CrossRef
  • Effect of zwitterionic sulfobetaine incorporation on blood behaviours, phagocytosis, and in vivo biodistribution of pH-responsive micelles with positive charges
    Chengwei Wang, Hao Liu, Hu Lin, Rui Zhong, Hao Li, Jiaxin Liu, Xianglin Luo, Meng Tian
    Journal of Materials Chemistry B.2024; 12(6): 1652.     CrossRef
  • Reexamining in vivo fate of paclitaxel-loaded polymeric micelles
    Shiqi Lin, Yifei Yu, Ercan Wu, Tianhao Ding, Yuxiu Chu, Feng Pan, Yang Yang, Changyou Zhan
    Nano Today.2024; 56: 102255.     CrossRef
  • Functionalized Polymeric Micelles for Targeted Cancer Therapy: Steps from Conceptualization to Clinical Trials
    Ana Serras, Célia Faustino, Lídia Pinheiro
    Pharmaceutics.2024; 16(8): 1047.     CrossRef
  • Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy
    Giuseppe Longobardi, Thomas Lee Moore, Claudia Conte, Francesca Ungaro, Ronit Satchi‐Fainaro, Fabiana Quaglia
    WIREs Nanomedicine and Nanobiotechnology.2024;[Epub]     CrossRef
  • Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer
    Jia-xin Qiao, Dong-yan Guo, Huan Tian, Zhan-peng Wang, Qiang-qiang Fan, Yuan Tian, Jing Sun, Xiao-fei Zhang, Jun-bo Zou, Jiang-xue Cheng, Fei Luan, Bing-tao Zhai
    Materials Today Bio.2024; 29: 101358.     CrossRef
  • Microwave‐Assisted Synthesis of Porous Biomolecule‐Incorporated Metal‐Organic Frameworks as Efficient Nanocarriers for Anti‐Cancer Drugs
    Trang Thi Thu Nguyen, Bao Quang Gia Le, Vy Tran Hanh Nguyen, Jae‐Hyoung Lee, Ngoc Xuan Dat Mai, Linh Ho Thuy Nguyen, Tan Le Hoang Doan
    ChemistrySelect.2023;[Epub]     CrossRef
  • Innovative nanotheranostics: Smart nanoparticles based approach to overcome breast cancer stem cells mediated chemo‐ and radioresistances
    Prithwish Kola, Prasanth Kumar Bhusetty Nagesh, Pritam Kumar Roy, K. Deepak, Rui Luis Reis, Subhas C. Kundu, Mahitosh Mandal
    WIREs Nanomedicine and Nanobiotechnology.2023;[Epub]     CrossRef
  • Nanoparticles in the diagnosis and treatment of cancer metastases: Current and future perspectives
    Mangala Hegde, Nikunj Naliyadhara, Jyothsna Unnikrishnan, Mohammed S. Alqahtani, Mohamed Abbas, Sosmitha Girisa, Gautam Sethi, Ajaikumar B. Kunnumakkara
    Cancer Letters.2023; 556: 216066.     CrossRef
  • Influence of lung cancer model characteristics on tumor targeting behavior of nanodrugs
    Weixia Xu, Shengmin Yang, Linwei Lu, Qianzhu Xu, Sunyi Wu, Jianfen Zhou, Jiashen Lu, Xingyan Fan, Nana Meng, Yuan Ding, Xudong Zheng, Weiyue Lu
    Journal of Controlled Release.2023; 354: 538.     CrossRef
  • Metastatic Breast Cancer: Review of Emerging Nanotherapeutics
    Ranga Dissanayake, Rheal Towner, Marya Ahmed
    Cancers.2023; 15(11): 2906.     CrossRef
  • Efficacy and Safety of Nanopaclitaxel Formulation for Cancer Treatment: Evidence From Randomized Clinical Trials
    Xiangmin Deng, Xiaoqin Huang, Xiaoyan Dong, Genxiang Mao, Wenmin Xing
    Nanomedicine.2023; 18(10): 833.     CrossRef
  • Combination Therapy as a Promising Way to Fight Oral Cancer
    João P. N. Silva, Bárbara Pinto, Luís Monteiro, Patrícia M. A. Silva, Hassan Bousbaa
    Pharmaceutics.2023; 15(6): 1653.     CrossRef
  • Nano delivery system for paclitaxel: Recent advances in cancer theranostics
    Na Ying, Sisi Liu, Mengmeng Zhang, Jing Cheng, Linghuan Luo, Jiayi Jiang, Gaofan Shi, Shu Wu, Jun Ji, Haoyuan Su, Hongzhi Pan, Dongdong Zeng
    Colloids and Surfaces B: Biointerfaces.2023; 228: 113419.     CrossRef
  • Current Perspectives on Paclitaxel: Focus on Its Production, Delivery and Combination Therapy
    Yibin Liu, Fenglan Zhao, Qibao Wang, Qingjie Zhao, Guige Hou, Qingguo Meng
    Mini-Reviews in Medicinal Chemistry.2023; 23(18): 1780.     CrossRef
  • Current perspectives and trends in nanoparticle drug delivery systems in breast cancer: bibliometric analysis and review
    Sheng Sun, Ye-hui Wang, Xiang Gao, He-yong Wang, Lu Zhang, Na Wang, Chun-mei Li, Shao-quan Xiong
    Frontiers in Bioengineering and Biotechnology.2023;[Epub]     CrossRef
  • Paclitaxel prodrug-encapsulated polypeptide micelles with redox/pH dual responsiveness for cancer chemotherapy
    Jinyu Liu, Yanhao Zhang, Chao Liu, Yuhao Jiang, Zihao Wang, Xinsong Li
    International Journal of Pharmaceutics.2023; 645: 123398.     CrossRef
  • Biodegradable polyester-based nano drug delivery system in cancer chemotherapy: a review of recent progress (2021–2023)
    Zongheng Wang, Miaomiao Xiao, Fangliang Guo, Yue Yan, Hong Tian, Qianshi Zhang, Shuangyi Ren, Liqun Yang
    Frontiers in Bioengineering and Biotechnology.2023;[Epub]     CrossRef
  • Comparison of triblock copolymeric micelles based on α- and ε-poly(L-lysine): a Cornelian choice
    Franck Marquet, Viorica Patrulea, Gerrit Borchard
    Polymer Journal.2022; 54(2): 199.     CrossRef
  • Current understandings and clinical translation of nanomedicines for breast cancer therapy
    Yike Jiang, Ziyi Jiang, Mingzhe Wang, Lan Ma
    Advanced Drug Delivery Reviews.2022; 180: 114034.     CrossRef
  • Poly(ϵ-Caprolactone)-Methoxypolyethylene Glycol (PCL-MPEG)-Based Micelles for Drug-Delivery: The Effect of PCL Chain Length on Blood Components, Phagocytosis, and Biodistribution
    Zemin Hou, Wencheng Zhou, Xi Guo, Rui Zhong, Ao Wang, Jiehua Li, Ying Cen, Chao You, Hong Tan, Meng Tian
    International Journal of Nanomedicine.2022; Volume 17: 1613.     CrossRef
  • Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy
    Prashant Pandey, Dilip Kumar Arya, Mohan Kumar Ramar, Kumarappan Chidambaram, P.S. Rajinikanth
    Drug Discovery Today.2022; 27(9): 2526.     CrossRef
  • Biophysical Characterization of Interactions between Serum Albumin and Block Copolymer Micelles
    Catherine F. Dial, Richard A. Gemeinhart
    ACS Biomaterials Science & Engineering.2022; 8(7): 2899.     CrossRef
  • Micelles in Cancer Therapy: An Update on Preclinical and Clinical Status
    Rabia Aqeel, Nidhi Srivastava, Poonam Kushwaha
    Recent Patents on Nanotechnology.2022; 16(4): 283.     CrossRef
  • Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers
    Juanjuan Yang, Xiaojin Wang, Bingshun Wang, Kinam Park, Karen Wooley, Shiyi Zhang
    Advanced Drug Delivery Reviews.2022; 190: 114525.     CrossRef
  • In Vivo Sustained Release of the Retrograde Transport Inhibitor Retro-2.1 Formulated in a Thermosensitive Hydrogel
    Robin Vinck, Laetitia Anvi Nguyen, Mathilde Munier, Lucie Caramelle, Diana Karpman, Julien Barbier, Alain Pruvost, Jean-Christophe Cintrat, Daniel Gillet
    International Journal of Molecular Sciences.2022; 23(23): 14611.     CrossRef
  • Clinical Translation of Self‐Assembled Cancer Nanomedicines
    Peng Mi, Kanjiro Miyata, Kazunori Kataoka, Horacio Cabral
    Advanced Therapeutics.2021;[Epub]     CrossRef
  • From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review
    Guillermo Valdivia, Ángela Alonso-Diez, Dolores Pérez-Alenza, Laura Peña
    Frontiers in Veterinary Science.2021;[Epub]     CrossRef
  • Advanced Biotechnologies: Collections of Plant Cell Cultures As a Basis for Development and Production of Medicinal Preparations
    E. V. Popova, A. V. Nosov, M. V. Titova, D. V. Kochkin, A. A. Fomenkov, I. E. Kulichenko, A. M. Nosov
    Russian Journal of Plant Physiology.2021; 68(3): 385.     CrossRef
  • Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation
    Xin Luan, Hebao Yuan, Yudong Song, Hongxiang Hu, Bo Wen, Miao He, Huixia Zhang, Yan Li, Feng Li, Pan Shu, Joseph P. Burnett, Nathan Truchan, Maria Palmisano, Manjunath P. Pai, Simon Zhou, Wei Gao, Duxin Sun
    Biomaterials.2021; 275: 120910.     CrossRef
  • Breast cancer: Muscarinic receptors as new targets for tumor therapy
    Alejandro Español, Agustina Salem, Yamila Sanchez, María Elena Sales
    World Journal of Clinical Oncology.2021; 12(6): 404.     CrossRef
  • Direct Comparison of Analogous Amphiphilic Gradient and Block Polyoxazolines
    Lenka Loukotová, Pavel Švec, Ondřej Groborz, Tomáš Heizer, Hynek Beneš, Helena Raabová, Tereza Bělinová, Vít Herynek, Martin Hrubý
    Macromolecules.2021; 54(17): 8182.     CrossRef
  • Challenges towards Targeted Drug Delivery in Cancer Nanomedicines
    Muhammad Nadeem Hafeez, Christian Celia, Vilma Petrikaite
    Processes.2021; 9(9): 1527.     CrossRef
  • Drug Delivery of Natural Products Through Nanocarriers for Effective Breast Cancer Therapy: A Comprehensive Review of Literature
    Kah Min Yap, Mahendran Sekar, Shivkanya Fuloria, Yuan Seng Wu, Siew Hua Gan, Nur Najihah Izzati Mat Rani, Vetriselvan Subramaniyan, Chandrakant Kokare, Pei Teng Lum, M Yasmin Begum, Shankar Mani, Dhanalekshmi Unnikrishnan Meenakshi, Kathiresan V Sathasiva
    International Journal of Nanomedicine.2021; Volume 16: 7891.     CrossRef
  • Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)
    Sung-Bae Kim, Jae Hong Seo, Jin-Hee Ahn, Tae-Yong Kim, Seok Yun Kang, Joohyuk Sohn, Yaewon Yang, Kyong Hwa Park, Yong Wha Moon, Seungtaek Lim, Myoung Joo Kang, Koung Eun Yoon, Hyun Ju Cho, Keun Seok Lee
    Therapeutic Advances in Medical Oncology.2021;[Epub]     CrossRef
  • Self-assembly of oxidation-responsive polyethylene glycol-paclitaxel prodrug for cancer chemotherapy
    Chengyuan Dong, Quan Zhou, Jiajia Xiang, Fusheng Liu, Zhuxian Zhou, Youqing Shen
    Journal of Controlled Release.2020; 321: 529.     CrossRef
  • Clinical applications of nanomedicine in cancer therapy
    Mohammad Norouzi, Mehrnaz Amerian, Mahshid Amerian, Fatemeh Atyabi
    Drug Discovery Today.2020; 25(1): 107.     CrossRef
  • Improvement of Paclitaxel-Associated Adverse Reactions (ADRs) via the Use of Nano-Based Drug Delivery Systems: A Systematic Review and Network Meta-Analysis


    Pi-Ling Chou, Ya-Ping Huang, Meng-Hsuan Cheng, Kun-Ming Rau, Yi-Ping Fang
    International Journal of Nanomedicine.2020; Volume 15: 1731.     CrossRef
  • Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review
    Adam S. Komorowski, Helen J. MacKay, Rossanna C. Pezo
    Cancer Medicine.2020; 9(14): 5035.     CrossRef
  • Nanotechnology for angiogenesis: opportunities and challenges
    Saeid Kargozar, Francesco Baino, Sepideh Hamzehlou, Michael R. Hamblin, Masoud Mozafari
    Chemical Society Reviews.2020; 49(14): 5008.     CrossRef
  • Furry nanoparticles: synthesis and characterization of nanoemulsion-mediated core crosslinked nanoparticles and their robust stability in vivo
    Rena Tanaka, Koichi Arai, Jun Matsuno, Miyo Soejima, Ji Ha Lee, Rintaro Takahashi, Kazuo Sakurai, Shota Fujii
    Polymer Chemistry.2020; 11(27): 4408.     CrossRef
  • Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval
    Duhyeong Hwang, Jacob D. Ramsey, Alexander V. Kabanov
    Advanced Drug Delivery Reviews.2020; 156: 80.     CrossRef
  • What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right
    Duxin Sun, Simon Zhou, Wei Gao
    ACS Nano.2020; 14(10): 12281.     CrossRef
  • Synthesis of PCL–PEG–PCL Triblock Copolymer via Organocatalytic Ring-Opening Polymerization and Its Application as an Injectable Hydrogel—An Interdisciplinary Learning Trial
    Kaiting Wu, Lin Yu, Jiandong Ding
    Journal of Chemical Education.2020; 97(11): 4158.     CrossRef
  • Phytochemical-Based Nanomedicine for Advanced Cancer Theranostics: Perspectives on Clinical Trials to Clinical Use


    Madhusmita Dhupal, Devasish Chowdhury
    International Journal of Nanomedicine.2020; Volume 15: 9125.     CrossRef
  • A Compressive Review about Taxol®: History and Future Challenges
    Julia Gallego-Jara, Gema Lozano-Terol, Rosa Alba Sola-Martínez, Manuel Cánovas-Díaz, Teresa de Diego Puente
    Molecules.2020; 25(24): 5986.     CrossRef
  • Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of Cancer
    Ruben AG van Eerden, Ron HJ Mathijssen, Stijn LW Koolen
    International Journal of Nanomedicine.2020; Volume 15: 8151.     CrossRef
  • Basic principles of drug delivery systems – the case of paclitaxel
    S. Ezrahi, A. Aserin, N. Garti
    Advances in Colloid and Interface Science.2019; 263: 95.     CrossRef
  • Biomolecules Turn Self-Assembling Amphiphilic Block Co-polymer Platforms Into Biomimetic Interfaces
    Saziye Yorulmaz Avsar, Myrto Kyropoulou, Stefano Di Leone, Cora-Ann Schoenenberger, Wolfgang P. Meier, Cornelia G. Palivan
    Frontiers in Chemistry.2019;[Epub]     CrossRef
  • Polyester Nanoparticle Encapsulation Mitigates Paclitaxel-Induced Peripheral Neuropathy
    R. Ganugula, M. Deng, M. Arora, H.-L. Pan, M. N. V. Ravi Kumar
    ACS Chemical Neuroscience.2019; 10(3): 1801.     CrossRef
  • PEGylation of Ginsenoside Rg3-Entrapped Bovine Serum Albumin Nanoparticles: Preparation, Characterization, and In Vitro Biological Studies
    Lijun Zhang, Junfeng Hui, Pei Ma, Yu Mi, Daidi Fan, Chenhui Zhu, Lei Chi, Yanan Dong
    Journal of Nanomaterials.2019; 2019: 1.     CrossRef
  • Prevention of paclitaxel-induced neuropathy by formulation approach
    Xiaowei Zang, Jong Bong Lee, Kiran Deshpande, Olga B. Garbuzenko, Tamara Minko, Leonid Kagan
    Journal of Controlled Release.2019; 303: 109.     CrossRef
  • Current status of nanomedicine in the chemotherapy of breast cancer
    A. I. Fraguas-Sánchez, C. Martín-Sabroso, A. Fernández-Carballido, A. I. Torres-Suárez
    Cancer Chemotherapy and Pharmacology.2019; 84(4): 689.     CrossRef
  • A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
    Bhumsuk Keam, Keun-Wook Lee, Se-Hoon Lee, Jin-Soo Kim, Jin Ho Kim, Hong-Gyun Wu, Keun-Yong Eom, Suzy Kim, Soon-Hyun Ahn, Eun-Jae Chung, Seong Keun Kwon, Woo-Jin Jeong, Young Ho Jung, Ji-Won Kim, Dae Seog Heo
    The Oncologist.2019; 24(6): 751.     CrossRef
  • Advances in thermosensitive polymer-grafted platforms for biomedical applications
    Phung Ngan Le, Chan Khon Huynh, Ngoc Quyen Tran
    Materials Science and Engineering: C.2018; 92: 1016.     CrossRef
  • Supramolecular polymeric chemotherapy based on cucurbit[7]uril-PEG copolymer
    Hao Chen, Yueyue Chen, Han Wu, Jiang-Fei Xu, Zhiwei Sun, Xi Zhang
    Biomaterials.2018; 178: 697.     CrossRef
  • pH/NIR-Responsive Polypyrrole-Functionalized Fibrous Localized Drug-Delivery Platform for Synergistic Cancer Therapy
    Arjun Prasad Tiwari, Tae In Hwang, Jung-Mi Oh, Bikendra Maharjan, Sungkun Chun, Beom Su Kim, Mahesh Kumar Joshi, Chan Hee Park, Cheol Sang Kim
    ACS Applied Materials & Interfaces.2018; 10(24): 20256.     CrossRef
  • The Blood Clearance Kinetics and Pathway of Polymeric Micelles in Cancer Drug Delivery
    Xuanrong Sun, Guowei Wang, Hao Zhang, Shiqi Hu, Xin Liu, Jianbin Tang, Youqing Shen
    ACS Nano.2018; 12(6): 6179.     CrossRef
  • Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles
    Feng Li, Huixia Zhang, Miao He, Jinhui Liao, Nianhang Chen, Yan Li, Simon Zhou, Maria Palmisano, Alex Yu, Manjunath P. Pai, Hebao Yuan, Duxin Sun
    Molecular Pharmaceutics.2018; 15(10): 4505.     CrossRef
  • Emerging advances in P-glycoprotein inhibitory nanomaterials for drug delivery
    Longfa Kou, Rui Sun, Yangzom D. Bhutia, Qing Yao, Ruijie Chen
    Expert Opinion on Drug Delivery.2018; 15(9): 869.     CrossRef
  • The battle of “nano” paclitaxel
    Alexandros Marios Sofias, Michael Dunne, Gert Storm, Christine Allen
    Advanced Drug Delivery Reviews.2017;[Epub]     CrossRef
  • Overcoming the Road Blocks: Advancement of Block Copolymer Micelles for Cancer Therapy in the Clinic
    Loujin Houdaihed, James C. Evans, Christine Allen
    Molecular Pharmaceutics.2017; 14(8): 2503.     CrossRef
  • PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application
    Philip Grossen, Dominik Witzigmann, Sandro Sieber, Jörg Huwyler
    Journal of Controlled Release.2017; 260: 46.     CrossRef
  • Effect of Thermoresponsive Poly(L-lactic acid)–poly(ethylene glycol) Gel Injection on Left Ventricular Remodeling in a Rat Myocardial Infarction Model
    Shota Somekawa, Atsushi Mahara, Kazunari Masutani, Yoshiharu Kimura, Hiroshi Urakawa, Tetsuji Yamaoka
    Tissue Engineering and Regenerative Medicine.2017; 14(5): 507.     CrossRef
  • A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer
    Xin-shuai Wang, De-jiu Kong, Tzu-yin Lin, Xiao-cen Li, Yoshihiro Izumiya, Xue-zhen Ding, Li Zhang, Xiao-chen Hu, Jun-qiang Yang, She-gan Gao, Kit S Lam, Yuan-pei Li
    Acta Pharmacologica Sinica.2017; 38(6): 931.     CrossRef
  • 17,534 View
  • 637 Download
  • 73 Web of Science
  • 67 Crossref
Close layer
Blockade of Autophagy Aggravates Endoplasmic Reticulum Stress and Improves Paclitaxel Cytotoxicity in Human Cervical Cancer Cells
Li Xu, Jing-Hua Liu, Jing Zhang, Na Zhang, Zan-Hong Wang
Cancer Res Treat. 2015;47(2):313-321.   Published online September 11, 2014
DOI: https://doi.org/10.4143/crt.2013.222
AbstractAbstract PDFPubReaderePub
Purpose
Autophagy is one of the ways to degrade unfolded proteins after endoplasmic reticulum (ER) stress. The purpose of this study is to determine whether a blockade of autophagy leads to aggravated endoplasmic reticulum stress, which then induces cells apoptosis in HeLa cells treated with paclitaxel.
Materials and Methods
Autophagy activation and the proapoptotic effects were characterized using monodansylcadaverine labeling and Hoechest staining, respectively. A Western blot analysis was used to detect the expression of apoptotic and autophagy-related genes. A flow cytometry was used to assess the cell apoptosis ratio.
Results
Paclitaxel exposure induced the aggregation of autophagosomes in the cytoplasms of cervical cancer HeLa cells. The expression of Beclin 1 and LC3 II were upregulated, but p62 was downregulated, which suggests that autophagy was promoted by paclitaxel. On the other hand, the expression of GRP78 obviously increased, suggesting that ER stress was induced after paclitaxel treatment. The cell proliferation assay indicated that a knockdown of Beclin 1 sensitized HeLa cells to paclitaxel. Furthermore, paclitaxel-mediated apoptotic cell death was further potentiated by the pretreatment with autophagy inhibitor chloroquine or small interfering RNA against Beclin 1. These results suggest that an induction of autophagy by paclitaxel may induce cell survival rather than cell death in HeLa cells; moreover, inhibition of autophagy led to an aggravated ER stress and an induction of downstream apoptosis.
Conclusion
Our results reveal autophagy induced by paclitaxel conferred protection of tumor cells against apoptosis, and blockade of autophagy subsequently aggravated ER stress, enhancing the apoptosis associated with paclitaxel treatment in HeLa cells.

Citations

Citations to this article as recorded by  
  • Endoplasmic reticulum stress induced autophagy in cancer and its potential interactions with apoptosis and ferroptosis
    Haitang Liao, Shuang Liu, Qiang Ma, He Huang, Arul Goel, Pedram Torabian, Chakrabhavi Dhananjaya Mohan, Chenyang Duan
    Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.2025; 1872(1): 119869.     CrossRef
  • Autophagy in cancer resistance to paclitaxel: Development of combination strategies
    Jan Škubník, Vladimíra Svobodová Pavlíčková, Tomáš Ruml, Silvie Rimpelová
    Biomedicine & Pharmacotherapy.2023; 161: 114458.     CrossRef
  • Advances in autophagy modulation of natural products in cervical cancer
    Tao Tao, Ping Zhang, Zhi Zeng, Min Wang
    Journal of Ethnopharmacology.2023; 314: 116575.     CrossRef
  • Chloroquine Sensitizes Esophageal Carcinoma EC109 Cells to Paclitaxel by Inhibiting Autophagy
    Zichun Yuan, Jiajing Cai, Qin Du, Qiang Ma, Lei Xu, Yan Cai, Xiaowu Zhong, Xiaolan Guo
    Critical Reviews in Eukaryotic Gene Expression.2023; 33(6): 43.     CrossRef
  • New sight into interaction between endoplasmic reticulum stress and autophagy induced by vanadium in duck renal tubule epithelial cells
    Li Wang, Yueying Pan, Fan Yang, Xiaowang Guo, Junjun Peng, Xiaoyu Wang, Yukun Fang, Jing Chen, Xin Yi, Huabin Cao, Guoliang Hu
    Chemico-Biological Interactions.2022; 362: 109981.     CrossRef
  • Cisplatin and paclitaxel-loaded liposomes induced cervical cancer (HeLa) cell death with multiple copies of human papillomavirus by apoptosis and decreased their cytotoxic effect on non-tumor cells
    Paulo Emilio Feuser, Ellen De Pieri, Maria Eduarda Oliveira, Arthur Poester Cordeiro, Rodrigo Cercena, Pedro Henrique Hermes de Araújo, Alexandre Gonçalves Dal Bó, Ricardo Andrez Machado-de-Ávila
    Journal of Drug Delivery Science and Technology.2022; 73: 103457.     CrossRef
  • Mechanisms of cancer cell death induction by paclitaxel: an updated review
    Shuang Zhao, Yufei Tang, Ruohan Wang, Masoud Najafi
    Apoptosis.2022; 27(9-10): 647.     CrossRef
  • An Updated Review on Implications of Autophagy and Apoptosis in Tumorigenesis: Possible Alterations in Autophagy through Engineered Nanomaterials and Their Importance in Cancer Therapy
    Habib Ghaznavi, Milad Shirvaliloo, Amir Zarebkohan, Zinat Shams, Fatemeh Radnia, Zahra Bahmanpour, Saman Sargazi, Ramin Saravani, Sakine Shirvalilou, Omolbanin Shahraki, Sheida Shahraki, Ziba Nazarlou, Roghayeh Sheervalilou
    Molecular Pharmacology.2021; 100(2): 119.     CrossRef
  • Demethylzeylasteral (T-96) initiates extrinsic apoptosis against prostate cancer cells by inducing ROS-mediated ER stress and suppressing autophagic flux
    Dong-lin Yang, Ya-jun Zhang, Liu-jun He, Chun-sheng Hu, Li-xia Gao, Jiu-hong Huang, Yan Tang, Jie Luo, Dian-yong Tang, Zhong-zhu Chen
    Biological Research.2021;[Epub]     CrossRef
  • Perturbation-Based Modeling Unveils the Autophagic Modulation of Chemosensitivity and Immunogenicity in Breast Cancer Cells
    Isaac Quiros-Fernandez, Lucía Figueroa-Protti, Jorge L. Arias-Arias, Norman Brenes-Cordero, Francisco Siles, Javier Mora, Rodrigo Antonio Mora-Rodríguez
    Metabolites.2021; 11(9): 637.     CrossRef
  • Enhanced efficacy of propranolol therapy for infantile hemangiomas based on a mesoporous silica nanoplatform through mediating autophagy dysfunction
    Haiwei Wu, Xuan Wang, Hao Liang, Jiawei Zheng, Shengyun Huang, Dongsheng Zhang
    Acta Biomaterialia.2020; 107: 272.     CrossRef
  • Loss of tumor susceptibility gene 101 (TSG101) perturbs endoplasmic reticulum structure and function
    Zenia Kaul, Debdatto Mookherjee, Subhrangshu Das, Debmita Chatterjee, Saikat Chakrabarti, Oishee Chakrabarti
    Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.2020; 1867(9): 118741.     CrossRef
  • RSK2 protects human breast cancer cells under endoplasmic reticulum stress through activating AMPKα2-mediated autophagy
    Lan-Ya Li, Xi-Sha Chen, Kuan-Song Wang, Yi-Di Guan, Xing-Cong Ren, Dong-Sheng Cao, Xin-Yuan Sun, Ao-Xue Li, Yong-Guang Tao, Yi Zhang, Ming-Zhu Yin, Xin-Luan Wang, Ming-Hua Wu, Jin-Ming Yang, Yan Cheng
    Oncogene.2020; 39(43): 6704.     CrossRef
  • New Insights into Therapy-Induced Progression of Cancer
    Polina V. Shnaider, Olga M. Ivanova, Irina K. Malyants, Ksenia S. Anufrieva, Ilya A. Semenov, Marat S. Pavlyukov, Maria A. Lagarkova, Vadim M. Govorun, Victoria O. Shender
    International Journal of Molecular Sciences.2020; 21(21): 7872.     CrossRef
  • Kaempferol Induces Cell Death in A2780 Ovarian Cancer Cells and Increases Their Sensitivity to Cisplatin by Activation of Cytotoxic Endoplasmic Reticulum-Mediated Autophagy and Inhibition of Protein Kinase B
    Attalla Farag El-Kott, A. A. Shati, M. A. Al-Kahtani, S. A. Alharbi
    Folia Biologica.2020; 66(1): 36.     CrossRef
  • Targeted Codelivery of Docetaxel and Atg7 siRNA for Autophagy Inhibition and Pancreatic Cancer Treatment
    Miaozun Zhang, Wei Zhang, Guping Tang, Hebin Wang, Min Wu, Weiming Yu, Zhenfeng Zhou, Yiping Mou, Xingang Liu
    ACS Applied Bio Materials.2019; 2(3): 1168.     CrossRef
  • An ATG5 knockout promotes paclitaxel resistance in v-Ha-ras-transformed NIH 3T3 cells
    Seong Yun Eom, Sung-Hee Hwang, Hojin Yeom, Michael Lee
    Biochemical and Biophysical Research Communications.2019; 513(1): 234.     CrossRef
  • Resveratrol, an activator of SIRT1, improves ER stress by increasing clusterin expression in HepG2 cells
    Jinmi Lee, Seok-Woo Hong, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Cheol-Young Park, Ki-Won Oh, Sung-Woo Park, Won-Young Lee
    Cell Stress and Chaperones.2019; 24(4): 825.     CrossRef
  • Molecular Mechanisms Underlying Autophagy-Mediated Treatment Resistance in Cancer
    Cally J. Ho, Sharon M. Gorski
    Cancers.2019; 11(11): 1775.     CrossRef
  • A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells in vitro and xenografts in vivo through apoptosis and an incomplete autopaghy in breast cancer
    Buse Cevatemre, Merve Erkısa, Nazlihan Aztopal, Didem Karakas, Pınar Alper, Chrisiida Tsimplouli, Evangelia Sereti, Konstantinos Dimas, Elif I. Ikitimur Armutak, Ebru Gurel Gurevin, Ayca Uvez, Mattia Mori, Simone Berardozzi, Cinzia Ingallina, Ilaria D’Acq
    Pharmacological Research.2018; 129: 500.     CrossRef
  • Chitosan-based zinc oxide nanoparticle for enhanced anticancer effect in cervical cancer: A physicochemical and biological perspective
    Henghui Wu, Juxin Zhang
    Saudi Pharmaceutical Journal.2018; 26(2): 205.     CrossRef
  • Pro-survival autophagy and cancer cell resistance to therapy
    Chandan Kanta Das, Mahitosh Mandal, Donat Kögel
    Cancer and Metastasis Reviews.2018; 37(4): 749.     CrossRef
  • The Superior Antitumor Effect of Self-Assembled Paclitaxel Nanofilaments for Lung Cancer Cells
    Mengyu He, Jiali Zhu, Na Yu, Hui Kong, Xiaoning Zeng, Weiping Xie, Huae Xu
    Current Drug Delivery.2018; 16(2): 171.     CrossRef
  • Triptolide induces protective autophagy and apoptosis in human cervical cancer cells by downregulating Akt/mTOR activation
    Guangyi Qin, Ping Li, Zhuowei Xue
    Oncology Letters.2018;[Epub]     CrossRef
  • Upstream transcription factor 1 prompts malignancies of cervical cancer primarily by transcriptionally activating p65 expression
    Wen Wang, Shujuan Yao, Hongjing Jiang, Jing Dong, Xiujuan Cui, Xiangyu Tian, Yanyan Guo, Shiqian Zhang
    Experimental and Therapeutic Medicine.2018;[Epub]     CrossRef
  • Autophagy inhibitors chloroquine and LY294002 enhance temozolomide cytotoxicity on cutaneous melanoma cell lines in vitro
    Oxana O. Ryabaya, Andrey N. Inshakov, Angelina V. Egorova, Marina A. Emelyanova, Tatiana V. Nasedkina, Alexander S. Zasedatelev, Dmitry A. Khochenkov, Evgenia V. Stepanova
    Anti-Cancer Drugs.2017; 28(3): 307.     CrossRef
  • Endoplasmic Reticulum Stress and Homeostasis in Reproductive Physiology and Pathology
    Elif Guzel, Sefa Arlier, Ozlem Guzeloglu-Kayisli, Mehmet Tabak, Tugba Ekiz, Nihan Semerci, Kellie Larsen, Frederick Schatz, Charles Lockwood, Umit Kayisli
    International Journal of Molecular Sciences.2017; 18(4): 792.     CrossRef
  • Sensitivity to antitubulin chemotherapeutics is potentiated by a photoactivable nanoliposome
    Xiaobing Wang, Xiufang Liu, Yixiang Li, Pan Wang, Xiaolan Feng, Quanhong Liu, Fei Yan, Hairong Zheng
    Biomaterials.2017; 141: 50.     CrossRef
  • MicroRNA‐495 regulates starvation‐induced autophagy by targeting ATG3
    Wen Li, Yue Yang, Xiaoyan Hou, Haixia Zhuang, Zijun Wu, Zhiyi Li, Runmin Guo, Hao Chen, Chunxia Lin, Wangtao Zhong, Yusen Chen, Keng Wu, Liangqing Zhang, Du Feng
    FEBS Letters.2016; 590(6): 726.     CrossRef
  • ESCRT-0 dysfunction compromises autophagic degradation of protein aggregates and facilitates ER stress-mediated neurodegeneration via apoptotic and necroptotic pathways
    Ryuji Oshima, Takafumi Hasegawa, Keiichi Tamai, Naoto Sugeno, Shun Yoshida, Junpei Kobayashi, Akio Kikuchi, Toru Baba, Akira Futatsugi, Ikuro Sato, Kennichi Satoh, Atsushi Takeda, Masashi Aoki, Nobuyuki Tanaka
    Scientific Reports.2016;[Epub]     CrossRef
  • The effect of quercetin nanoparticle on cervical cancer progression by inducing apoptosis, autophagy and anti-proliferation via JAK2 suppression
    Cheng-lin Luo, Yu-qiong Liu, Peng Wang, Chun-hua Song, Kai-juan Wang, Li-ping Dai, Jian-ying Zhang, Hua Ye
    Biomedicine & Pharmacotherapy.2016; 82: 595.     CrossRef
  • Role of autophagy and lysosomal drug sequestration in acquired resistance to doxorubicin in MCF-7 cells
    Baoqing Guo, Adam Tam, Stacey A. Santi, Amadeo M. Parissenti
    BMC Cancer.2016;[Epub]     CrossRef
  • Blocking autophagy enhances meloxicam lethality to hepatocellular carcinoma by promotion of endoplasmic reticulum stress
    Jingtao Zhong, Xiaofeng Dong, Peng Xiu, Fuhai Wang, Ju Liu, Honglong Wei, Zongzhen Xu, Feng Liu, Tao Li, Jie Li
    Cell Proliferation.2015; 48(6): 691.     CrossRef
  • 8-p-Hdroxybenzoyl Tovarol Induces Paraptosis Like Cell Death and Protective Autophagy in Human Cervical Cancer HeLa Cells
    Cui Zhang, Yingnan Jiang, Jin Zhang, Jian Huang, Jinhui Wang
    International Journal of Molecular Sciences.2015; 16(7): 14979.     CrossRef
  • 15,621 View
  • 137 Download
  • 39 Web of Science
  • 34 Crossref
Close layer
Synergistic Effect of COX-2 Inhibitor on Paclitaxel-Induced Apoptosis in the Human Ovarian Cancer Cell Line OVCAR-3
Hee Jung Kim, Ga Won Yim, Eun Ji Nam, Young Tae Kim
Cancer Res Treat. 2014;46(1):81-92.   Published online January 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.1.81
AbstractAbstract PDFPubReaderePub
PURPOSE
Celecoxib, a highly selective cyclooxygenase-2 inhibitor, regulates apoptosis of several types of human cancer cells. The purpose of this study was to investigate whether celecoxib in combination with paclitaxel modulates apoptosis of ovarian cancer cells, and to identify the signal pathway by which celecoxib mediates apoptosis.
MATERIALS AND METHODS
OVCAR-3 cells were exposed to paclitaxel (20 microM) in the absence or presence of celecoxib (10 microM). Cell viability was evaluated using a Cell Counting Kit-8 assay. Apoptosis was evaluated using Annexin-V/7-aminoactinomycin D staining and a cellular DNA fragmentation enzyme-linked immunosorbent assay. Caspase-3, -9, and cleavage of poly ADP-ribose polymerase (PARP) were determined by western blotting. Expression of nuclear factor-kappaB (NF-kappaB) and vascular endothelial growth factor (VEGF) and Akt activation were assessed using reverse transcriptase-polymerase chain reaction and western blotting.
RESULTS
Celecoxib enhanced paclitaxel-induced growth inhibition of OVCAR-3 cells. Celecoxib significantly increased paclitaxel-induced apoptosis of OVCAR-3 cells. Pretreatment with celecoxib also increased activation of caspase-9, -3 and cleaved PARP following paclitaxel-treatment. Exposure of OVCAR-3 cells to celecoxib in combination with paclitaxel resulted in downregulation of NF-kappaB activation and VEGF expression. Furthermore, combining celecoxib and paclitaxel inhibited phosphorylation of Akt.
CONCLUSION
OVCAR-3 cells were sensitized to paclitaxel-induced apoptosis by celecoxib through downregulation of NF-kappaB and Akt activation, suggesting that celecoxib may work synergistically with paclitaxel to inhibit different targets and ultimately produce anticancer effects. Combining celecoxib with paclitaxel may prove beneficial in the clinical treatment of ovarian cancer.

Citations

Citations to this article as recorded by  
  • Concomitant effects of paclitaxel and celecoxib on genes involved in apoptosis of triple-negative metastatic breast cancer cells
    Mohaddeseh Hedayat, Mohammad Rafi Khezri, Reza Jafari, Hassan Malekinejad, Naime Majidi Zolbanin
    Medical Oncology.2023;[Epub]     CrossRef
  • Hyperforin-mediated anticancer mechanisms in MDA-MB-231 cell line: insights into apoptotic mediator modulation and caspase activation
    Muttiah Barathan, Ahmad Khusairy Zulpa, Kumutha Malar Vellasamy, Zaridatul Aini Ibrahim, See Mee Hoong, Vanitha Mariappan, Gopinath Venkatraman, Jamuna Vadivelu
    Journal of Taibah University for Science.2023;[Epub]     CrossRef
  • Celecoxib Reverse Invasion and Metastasis of Gastric Cancer through Lnc_AC006548.28-miR-223-LAMC2 Pathway
    Guohua Jin, Jianguang Zhang, Tingting Cao, He Zhu, Yang Shi, Kapil Sharma
    Computational Intelligence and Neuroscience.2022; 2022: 1.     CrossRef
  • New Visions on Natural Products and Cancer Therapy: Autophagy and Related Regulatory Pathways
    Alma Martelli, Marzieh Omrani, Maryam Zarghooni, Valentina Citi, Simone Brogi, Vincenzo Calderone, Antoni Sureda, Shahrokh Lorzadeh, Simone C. da Silva Rosa, Beniamin Oscar Grabarek, Rafał Staszkiewicz, Marek J. Los, Seyed Fazel Nabavi, Seyed Mohammad Nab
    Cancers.2022; 14(23): 5839.     CrossRef
  • MicroRNA-758 Regulates Oral Squamous Cell Carcinoma via COX-2
    Gang Dong, Hong Chen, Yan Shi, Chunrong Jiang, Hongtao Yang
    Indian Journal of Surgery.2021; 83(4): 932.     CrossRef
  • Synergistic effects of green tea extract and paclitaxel in the induction of mitochondrial apoptosis in ovarian cancer cell lines
    Mohammad Panji, Vahideh Behmard, Zahra Zare, Monireh Malekpour, Hasan Nejadbiglari, Saeede Yavari, Tina Nayerpour dizaj, Azadeh Safaeian, Ali Bakhshi, Omid Abazari, Mojtaba Abbasi, Parisa Khanicheragh, Maryam Shabanzadeh
    Gene.2021; 787: 145638.     CrossRef
  • Spike-in normalization for single-cell RNA-seq reveals dynamic global transcriptional activity mediating anticancer drug response
    Xin Wang, Jane Frederick, Hongbin Wang, Sheng Hui, Vadim Backman, Zhe Ji
    NAR Genomics and Bioinformatics.2021;[Epub]     CrossRef
  • Identification of Key Genes and Pathways Associated With Paclitaxel Resistance in Esophageal Squamous Cell Carcinoma Based on Bioinformatics Analysis
    Zhimin Shen, Mingduan Chen, Fei Luo, Hui Xu, Peipei Zhang, Jihong Lin, Mingqiang Kang
    Frontiers in Genetics.2021;[Epub]     CrossRef
  • Cyclooxygenase-2 promotes ovarian cancer cell migration and cisplatin resistance via regulating epithelial mesenchymal transition
    Lin Deng, Ding-qing Feng, Bin Ling
    Journal of Zhejiang University-SCIENCE B.2020; 21(4): 315.     CrossRef
  • Paclitaxel induces apoptosis through the TAK1–JNK activation pathway
    Di Yu‐Wei, Zhuo‐sheng Li, Shu‐min Xiong, Ge Huang, Yan‐fei Luo, Tie‐ying Huo, Mao‐hua Zhou, You‐wei Zheng
    FEBS Open Bio.2020; 10(8): 1655.     CrossRef
  • Integration of genetic variants and gene network for drug repurposing in colorectal cancer
    Lalu Muhammad Irham, Henry Sung-Ching Wong, Wan-Hsuan Chou, Wirawan Adikusuma, Eko Mugiyanto, Wan-Chen Huang, Wei-Chiao Chang
    Pharmacological Research.2020; 161: 105203.     CrossRef
  • Correlation between the changes of serum COX 2, APE1, VEGF, TGF-β and TSGF levels and prognosis in patients with osteosarcoma before and after treatment
    Qingxi Zhang, Guo Dong, Fuchuan Wang, Wenyuan Ding
    Journal of Cancer Research and Therapeutics.2020; 16(2): 335.     CrossRef
  • Preventative effect of celecoxib in dimethylbenz[a]anthracene-induced ovarian cancer in rats
    Zhuyan Shao, Qiang Wen, Tao Zhu, Wei Jiang, Yu Kang, Conjian Xu, Shihua Wang
    Archives of Gynecology and Obstetrics.2018; 298(5): 981.     CrossRef
  • Cyclooxygenase-1 (COX-1) and COX-1 Inhibitors in Cancer: A Review of Oncology and Medicinal Chemistry Literature
    Alessandra Pannunzio, Mauro Coluccia
    Pharmaceuticals.2018; 11(4): 101.     CrossRef
  • Targeting multidrug-resistant ovarian cancer through estrogen receptor α dependent ATP depletion caused by hyperactivation of the unfolded protein response
    Xiaobin Zheng, Neal Andruska, Michael J. Lambrecht, Sisi He, Amadeo Parissenti, Paul J. Hergenrother, Erik R. Nelson, David J. Shapiro
    Oncotarget.2018; 9(19): 14741.     CrossRef
  • MicroRNA-381 regulates the occurrence and immune responses of coronary atherosclerosis via cyclooxygenase-2
    Kaiyou Song, Lianting Li, Guiling Sun, Yanjin Wei
    Experimental and Therapeutic Medicine.2018;[Epub]     CrossRef
  • Cyclooxygenase-2 mediated synergistic effect of ursolic acid in combination with paclitaxel against human gastric carcinoma
    Xian Xu, Guo-Qin Zhu, Kai Zhang, Yi-Chan Zhou, Xiao-Lin Li, Wei Xu, Hao Zhang, Yun Shao, Zhen-Yu Zhang, Wei-Hao Sun
    Oncotarget.2017; 8(54): 92770.     CrossRef
  • Literature-based discovery of new candidates for drug repurposing
    Hsih-Te Yang, Jiun-Huang Ju, Yue-Ting Wong, Ilya Shmulevich, Jung-Hsien Chiang
    Briefings in Bioinformatics.2016; : bbw030.     CrossRef
  • Synergistic growth inhibitory effect of deracoxib with doxorubicin against a canine mammary tumor cell line, CMT-U27
    Tülay BAKIREL, Fulya Üstün ALKAN, Oya ÜSTÜNER, Suzan ÇINAR, Funda YILDIRIM, Gaye ERTEN, Utku BAKIREL
    Journal of Veterinary Medical Science.2016; 78(4): 657.     CrossRef
  • Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer
    Andrew J. Wilson, Oluwole Fadare, Alicia Beeghly-Fadiel, Deok-Soo Son, Qi Liu, Shilin Zhao, Jeanette Saskowski, Md. Jashim Uddin, Cristina Daniel, Brenda Crews, Brian D. Lehmann, Jennifer A. Pietenpol, Marta A. Crispens, Lawrence J. Marnett, Dineo Khabele
    Oncotarget.2015; 6(25): 21353.     CrossRef
  • 13,110 View
  • 120 Download
  • 25 Web of Science
  • 20 Crossref
Close layer
Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer
Hee Seung Kim, Mi-Kyung Kim, Hak Jae Kim, Seung-Su Han, Jae Weon Kim
Cancer Res Treat. 2012;44(2):97-103.   Published online June 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.2.97
AbstractAbstract PDFPubReaderePub
PURPOSE
This study investigated the efficacy and toxicity associated with consolidation chemotherapy using paclitaxel and carboplatin after concurrent chemoradiation (CCR) in cervical cancer patients.
MATERIALS AND METHODS
From a total of 37 patients, 19 with International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IIA cervical cancer (group 1) underwent surgery followed by consolidation chemotherapy after CCR, and 18 with stage IIB-IVA disease (group 2) received consolidation chemotherapy after primary CCR. Three cycles of chemotherapy using paclitaxel (135 mg/m2) and carboplatin (AUC 5.0) were administered every 3 weeks for CCR therapy, and three cycles of consolidation chemotherapy using paclitaxel (175 mg/m2) and carboplatin (AUC 5.0) were used every 3 weeks after CCR.
RESULTS
The complete and partial response rates were 77.8% and 22.2% in group 2. Moreover, the 3-year progression-free and overall survival rates were 62.7% and 90.9% in group 1, and 51.9% and 60% in group 2, respectively. The most common grade 3 or 4 hematologic toxicities observed were leukopenia (group 1, 10.5%; group 2, 13.0%) and neutropenia (group 1, 7.0%; group 2, 14.8%), and grade 3 or 4 diarrhea (group 1, 1.8%) and febrile illness (group 2, 1.9%) were the most frequently observed non-hematologic toxicities. When we compared these results with previous reports, consolidation chemotherapy after CCR using paclitaxel and carboplatin revealed a relatively lower complete response rate (77.8% vs. 87-100%, respectively) and shorter progression-free survival (51.9-62.7% vs. 81-86%, respectively) and overall survival (60-90.9% vs. 81-95%, respectively) in spite of similar toxicity findings.
CONCLUSION
Due to low efficacy results, consolidation chemotherapy using paclitaxel and carboplatin after CCR is not a feasible treatment regimen for high-risk early-stage or locally advanced cervical cancer.

Citations

Citations to this article as recorded by  
  • Radiomics feature is a risk factor for locally advanced cervical cancer treated using concurrent chemoradiotherapy based on magnetic resonance imaging: a retrospective study
    Yuan Wang, Yanyan Yu, Lina Gu, Yunfeng Sun, Jiazhuo Yan, Hongxia Zhang, Yunyan Zhang
    BMC Cancer.2025;[Epub]     CrossRef
  • Efficacy and safety of consolidation chemotherapy after adjuvant therapy in stage IB-IIA cervical cancer patients with risk factors: a retrospective single-center study
    Jiaxin Wang, Huaijuan Guo, Jingjing Yang, Jingxian Mao, Ying Wang, Ruidong Gao, Xuebing Yan, Jie Wang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • The effectiveness of consolidation chemotherapy in high-risk early-stage cervical cancer patients following concurrent chemoradiation after radical surgery
    Cong Wang, Chunli Fu, Changdong Ma, Qiuhong Qian, Fangfang He, Guangyu Zhang
    Japanese Journal of Clinical Oncology.2023; 53(2): 122.     CrossRef
  • Efficacy and safety of adjuvant chemotherapy for locally advanced cervical cancer: A systematic review and meta-analysis
    Xiao Ma, Jin Fang, Lu Zhang, Yao Huang, Hui Shen, Xiaohua Ma, Shuixing Zhang, Bin Zhang
    Critical Reviews in Oncology/Hematology.2023; 184: 103953.     CrossRef
  • The effect of consolidation chemotherapy after concurrent chemoradiation on the prognosis of locally advanced cervical cancer: a systematic review and meta-analysis
    Lan Zhong, Kemin Li, Liang Song, Rutie Yin
    Journal of Obstetrics and Gynaecology.2022; 42(5): 830.     CrossRef
  • Role of Adjuvant Chemotherapy After Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer
    Lingna Kou, Tao Zhang, Xiling Yang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin Li
    Future Oncology.2022; 18(16): 1917.     CrossRef
  • Integration of Consolidation Chemotherapy After Concurrent Chemoradiation in the Treatment of Locally Advanced Uterine Cervical Cancer
    V. S. Haritha, Laxmi Singotia, Rajesh Jain, A. K. Saxena, Shyamji Rawat, Lalit Patel
    Indian Journal of Gynecologic Oncology.2022;[Epub]     CrossRef
  • A Multi-Institutional Retrospective Analysis of Oncologic Outcomes for Patients With Locally Advanced Cervical Cancer Undergoing Platinum-Based Adjuvant Chemotherapy After Concurrent Chemoradiotherapy
    Ning Wu, Xing Su, Honglin Song, Ying Li, Fei Gu, Xiaoge Sun, Xiaofan Li, Guanghui Cheng
    Cancer Control.2021;[Epub]     CrossRef
  • Adjuvant Systemic Therapy after Chemoradiation and Brachytherapy for Locally Advanced Cervical Cancer: A Systematic Review and Meta-Analysis
    Nanda Horeweg, Prachi Mittal, Patrycja L. Gradowska, Ingrid Boere, Supriya Chopra, Remi A. Nout
    Cancers.2021; 13(8): 1880.     CrossRef
  • How should we stage and tailor treatment strategy in locally advanced cervical cancer? Imaging versus para-aortic surgical staging
    Alejandra Martinez, Martina Aida Angeles, Denis Querleu, Gwenael Ferron, Christophe Pomel
    International Journal of Gynecological Cancer.2020; 30(9): 1434.     CrossRef
  • Clinical Analysis of Apatinib in the Treatment of Patients with Residual Tumor after Radical Chemoradiotherapy for Locally Advanced Cervical Cancer
    Jun Jiang, Wei Hong Wei, Tao Xu
    Journal of Cancer Research Updates.2020; 9(1): 20.     CrossRef
  • Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients
    Seiji Mabuchi, Fumiaki Isohashi, Mika Okazawa, Fuminori Kitada, Shintaro Maruoka, Kazuhiko Ogawa, Tadashi Kimura
    Journal of Gynecologic Oncology.2017;[Epub]     CrossRef
  • Clinical outcomes in patients treated with radiotherapy after surgery for cervical cancer
    Kyungmi Yang, Won Park, Seung Jae Huh, Duk-Soo Bae, Byoung-Gie Kim, Jeong-Won Lee
    Radiation Oncology Journal.2017; 35(1): 39.     CrossRef
  • Substantieller Vorteil durch CT-geplante HDR-Brachytherapie bei Zervixkarzinompatientinnen im Vergleich zu historischen Serien bezüglich lokaler Kontrolle und Toxizität?
    Simone Marnitz
    Strahlentherapie und Onkologie.2017; 193(3): 236.     CrossRef
  • CT-geplante HDR-Brachytherapie
    Simone Marnitz-Schulze
    InFo Onkologie.2017; 20(4): 10.     CrossRef
  • Prognostic Value of Log Odds of Positive Lymph Nodes after Radical Surgery Followed by Adjuvant Treatment in High-Risk Cervical Cancer
    Jeanny Kwon, Keun-Yong Eom, In Ah Kim, Jae-Sung Kim, Young-Beom Kim, Jae Hong No, Kidong Kim
    Cancer Research and Treatment.2016; 48(2): 632.     CrossRef
  • A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes
    Seiji Mabuchi, Fumiaki Isohashi, Takeshi Yokoi, Masahiko Takemura, Kiyoshi Yoshino, Yasuhiko Shiki, Kimihiko Ito, Takayuki Enomoto, Kazuhiko Ogawa, Tadashi Kimura
    Gynecologic Oncology.2016; 141(2): 240.     CrossRef
  • Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer
    Yu Chang, Zhi-Yong Yang, Gui-Ling Li, Qin Li, Qin Yang, Ji-Quan Fan, Ying-Chao Zhao, Ying-Qiu Song, Gang Wu
    International Journal of Gynecological Cancer.2016; 26(4): 770.     CrossRef
  • Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy
    Wenze Sun, Tao Wang, Fan Shi, Jiquan Wang, Juan Wang, Beina Hui, Yingbing Zhang, Jinli Lu, Hongwei Chen, Zi Liu
    BMC Cancer.2015;[Epub]     CrossRef
  • Time-window of early detection of response to concurrent chemoradiation in cervical cancer by using diffusion-weighted MR imaging: a pilot study
    Ying Liu, Haoran Sun, Renju Bai, Zhaoxiang Ye
    Radiation Oncology.2015;[Epub]     CrossRef
  • Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer
    Siriwan Tangjitgamol, Kanyarat Katanyoo, Malinee Laopaiboon, Pisake Lumbiganon, Sumonmal Manusirivithaya, Busaba Supawattanabodee
    Cochrane Database of Systematic Reviews.2014;[Epub]     CrossRef
  • Comparison of Clinical Efficacy of Three Different Neoadjuvant Approaches (Chemotherapy Combined Vaginal Intracavitary Irradiation, Neoadjuvant Chemotherapy Alone or Radiotherapy) Combined with Surgery for Patients with Stage Ib2 and IIa2 Cervical Cancer
    Jian-Hong Fu, Zhan Gao, Chen-Chen Ren, Yong-Gang Shi
    Asian Pacific Journal of Cancer Prevention.2013; 14(4): 2377.     CrossRef
  • A Phase I Study of Concurrent Weekly Carboplatin and Paclitaxel Combined With Intensity-Modulated Pelvic Radiotherapy as an Adjuvant Treatment for Early-Stage Cervical Cancer Patients With Positive Pelvic Lymph Nodes
    Seiji Mabuchi, Ryoko Takahashi, Fumiaki Isohashi, Takeshi Yokoi, Kimihiko Ito, Tateki Tsutui, Toshiyuki Ogata, Yasuo Yoshioka, Kazuhiko Ogawa, Tadashi Kimura
    International Journal of Gynecological Cancer.2013; 23(7): 1279.     CrossRef
  • 10,675 View
  • 97 Download
  • 23 Crossref
Close layer
Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials
Hong Jae Chon, Sun Young Rha, Chong Kun Im, Chan Kim, Min Hee Hong, Hye Ryun Kim, Jung Ryun An, Sung Hoon Noh, Hyun Cheol Chung, Hei-Cheul Jeung
Cancer Res Treat. 2009;41(4):196-204.   Published online December 31, 2009
DOI: https://doi.org/10.4143/crt.2009.41.4.196
AbstractAbstract PDFPubReaderePub
Purpose

This is an ad hoc analysis of two phase II studies which compared the efficacy and safety of two taxanes (paclitaxel and docetaxel) combined with 5-fluorouracil (5-FU) and leucovorin (LV) in advanced gastric cancer.

Materials and Methods

Patients with advanced gastric adenocarcinoma who were untreated or had only received first-line chemotherapy, were treated with either paclitaxel (PFL; 175 mg/m2) or docetaxel (DFL; 75 mg/m2) on day 1, followed by a bolus of LV (20 mg/m2 days 1~3) and a 24-hour infusion of 5-FU (1,000 mg/m2 days 1~3) every 3 weeks. The primary endpoint was overall response rate (ORR) and the secondary endpoint included survival and toxicity.

Results

Sixty-six patients received DFL (first-line [n=38]; and second-line [n=28]) and 60 patients received PFL (first-line [n=37]; and second-line [n=23]). The ORRs were not significantly different between the 2 groups (DFL, 26%; PFL, 38%). With a median follow-up of 9.5 months, the progression free survival was 5.2 months (95% confidence interval [CI], 4.2~6.5 months) for DFL and 3.3 months (95% CI, 1.3~5.5 months) for PFL (p=0.17). The overall survival was also comparable between the patients who received DFL and PFL (10.0 months [95% CI, 7.2~12.5 months] and 13.9 months [95% CI, 10.9~19.2 months], respectively; p=0.37). The most frequent grade 3~4 adverse event was neutropenia (DFL, 71%; PFL, 62%). DFL and PFL had different non-hematologic toxicities; specifically, grade ≥3 mucositis (5%) and diarrhea (3%) were common in DFL, while nausea/vomiting (15%) and peripheral neuropathy (5%) were common in PFL.

Conclusion

Thus, the two taxanes had similar efficacy in the treatment of advanced gastric cancer, but different toxicity profiles. Prospective comparative studies are required to further clarify the role of taxanes in the treatment of advanced gastric cancer.

Citations

Citations to this article as recorded by  
  • Drug-Induced Peripheral Neuropathy: Diagnosis and Management
    Diala Merheb, Georgette Dib, Maroun Bou Zerdan, Clara El Nakib, Saada Alame, Hazem I. Assi
    Current Cancer Drug Targets.2022; 22(1): 49.     CrossRef
  • Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study
    Hieu Trong Nguyen, Kien Hung Do, Nguyen Ba Le, Thang Tran
    Cancer Management and Research.2022; Volume 14: 2825.     CrossRef
  • Role for Drug Transporters in Chemotherapy‐Induced Peripheral Neuropathy
    Tore B. Stage, Shuiying Hu, Alex Sparreboom, Deanna L. Kroetz
    Clinical and Translational Science.2021; 14(2): 460.     CrossRef
  • Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
    Daniel V.T. Catenacci, Stephanie Moya, Samantha Lomnicki, Leah M. Chase, Bryan F. Peterson, Natalie Reizine, Lindsay Alpert, Namrata Setia, Shu-Yuan Xiao, John Hart, Uzma D. Siddiqui, D. Kyle Hogarth, Oliver S. Eng, Kiran Turaga, Kevin Roggin, Mitchell C.
    Cancer Discovery.2021; 11(2): 308.     CrossRef
  • Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy
    Giulia Fumagalli, Laura Monza, Guido Cavaletti, Roberta Rigolio, Cristina Meregalli
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems
    Nathan P. Staff, Jill C. Fehrenbacher, Martial Caillaud, M. Imad Damaj, Rosalind A. Segal, Sandra Rieger
    Experimental Neurology.2020; 324: 113121.     CrossRef
  • Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma
    Yoko Tomita, Max Moldovan, Rachael Chang Lee, Amy HC Hsieh, Amanda Townsend, Timothy Price
    Cochrane Database of Systematic Reviews.2020;[Epub]     CrossRef
  • Paclitaxel, 5-fluorouracil, and leucovorin combination chemotherapy as first-line treatment in patients with advanced gastric cancer
    Wan-Cai Que, Yan-Fang Huang, Xiao-Yan Lin, Yan-Qin Lan, Xin-Yan Gao, Xin-Li Wang, Ri-Ping Wu, Bin Du, Xiao-Bin Huang, Hong-qiang Qiu, Dong-Ta Zhong
    Anti-Cancer Drugs.2019; 30(3): 302.     CrossRef
  • Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer
    Chan Kim, Hong Jae Chon, Joo Hoon Kim, Minkyu Jung, Chung Mo Nam, Hyo Song Kim, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha
    European Journal of Cancer.2019; 112: 20.     CrossRef
  • Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
    Peter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, Eric Van Cutsem, Jaffer A Ajani, Hugo Castro, Wasat Mansoor, Hyun Cheol Chung, Gyorgy Bodoky, Kohei Shitara, Gail D Lewis Phillips, Tina van der Horst, Marie-Laurence Harle-Yge, Betsy L Althaus, Yoon-K
    The Lancet Oncology.2017; 18(5): 640.     CrossRef
  • Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
    Hana Starobova, Irina Vetter
    Frontiers in Molecular Neuroscience.2017;[Epub]     CrossRef
  • Identifying therapeutic targets in gastric cancer: the current status and future direction
    Beiqin Yu, Jingwu Xie
    Acta Biochimica et Biophysica Sinica.2016; 48(1): 90.     CrossRef
  • Role of Transient Receptor Potential Channels in Paclitaxel- and Oxaliplatin-induced Peripheral Neuropathy
    Kyoji Taguchi
    YAKUGAKU ZASSHI.2016; 136(2): 287.     CrossRef
  • Paclitaxel combined with oxaliplatin as first-line chemotherapy for locally advanced or metastatic gastric cancer
    Chunmei Shi, Qiang Chen, Songfei Shen, Riping Wu, Baoyu Yang, Qing Liu, Qian Xu
    Expert Review of Anticancer Therapy.2015; 15(5): 595.     CrossRef
  • Corosolic acid enhances 5-fluorouracil-induced apoptosis against SNU-620 human gastric carcinoma cells by inhibition of mammalian target of rapamycin
    HYUN SU LEE, JUN BEOM PARK, MYUNG SUN LEE, EUN YOUNG CHA, JI YEON KIM, JI YOUNG SUL
    Molecular Medicine Reports.2015; 12(3): 4782.     CrossRef
  • Paclitaxel-based regimens as first-line treatment in advanced gastric cancer
    Zengqing Guo, Xiaojie Wang, Rongbo Lin, Ling Chen, Nanfeng Fan, Yu Chen, Jinyuan Lin, Jiami Yu
    Journal of Chemotherapy.2015; 27(2): 94.     CrossRef
  • A phase 2 study of fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as a salvage treatment in patients with refractory or relapsed advanced gastric cancer
    Rongbo Lin, Nanfeng Fan, Guangfeng Wu, Ying Chen, Zengqing Guo, Xiaojie Wang, Feng Jin, Ling Chen, Jie Liu
    Journal of Chemotherapy.2015; 27(1): 52.     CrossRef
  • Paclitaxel combined with capecitabine as first-line chemotherapy for advanced or recurrent gastric cancer
    MEIQIN YUAN, YUNSHAN YANG, WANGXIA LV, ZHENGBO SONG, HAIJUN ZHONG
    Oncology Letters.2014; 8(1): 351.     CrossRef
  • Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
    Andreas A. Argyriou, Jordi Bruna, Paola Marmiroli, Guido Cavaletti
    Critical Reviews in Oncology/Hematology.2012; 82(1): 51.     CrossRef
  • Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention
    W. Grisold, G. Cavaletti, A. J. Windebank
    Neuro-Oncology.2012; 14(suppl 4): iv45.     CrossRef
  • Successful Treatment of a Patient with HER2-Positive Metastatic Gastric Cancer with Third-Line Combination Therapy with Irinotecan, 5-Fluorouracil, Leucovorin and Trastuzumab (FOLFIRI-T)
    Florian Weissinger, Marc Reymond, Klaus Dumke, Martin Krüger
    Onkologie.2011; 34(10): 548.     CrossRef
  • RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase
    Kyung-Hun Lee, Hyung-Seok Hur, Seock-Ah Im, Juhee Lee, Hwang-Phill Kim, Young-Kwang Yoon, Sae-Won Han, Sang-Hyun Song, Do-Youn Oh, Tae-You Kim, Yung-Jue Bang
    Cancer Letters.2010; 299(1): 22.     CrossRef
  • 12,206 View
  • 76 Download
  • 22 Crossref
Close layer
A Phase II Trial of Paclitaxel, 5-fluorouracil (5-FU) and Cisplatin in Patients with Metastatic or Recurrent Gastric Cancer
Gun Hi Kang, Gwang Sil Kim, Hyo Rak Lee, Young Jin Yuh, Sung Rok Kim
Cancer Res Treat. 2008;40(3):106-110.   Published online September 30, 2008
DOI: https://doi.org/10.4143/crt.2008.40.3.106
AbstractAbstract PDFPubReaderePub
Purpose

We wanted to assess the effectiveness and safety of combination chemotherapy with paclitaxel, 5-fluorouracil (5-FU) and cisplatin for treating advanced gastric cancer.

Materials and Methods

Patients with metastatic or recurrent gastric cancer were entered into this study. Paclitaxel at a dose of 135 mg/m2 on day 1, 5-FU 1 g/m2/day in a 24 hour continuous infusion from day 1 to day 4 and cisplatin 60 mg/m2 on day 1 were administered. This regimen was repeated every 3 weeks.

Results

A total of 34 patients were enrolled in this study. Among them, 33 patients were finally evaluable for their response. 17 (51.5%) patients had a partial response (95% CI: 26.0~77.0%). The median duration of overall survival was 13.2 months. Grade 3 or 4 neutropenia and thrombocytopenia were observed in 15.2% and 1.1% of all the cycles, respectively. Grade 3 stomatitis and neurotoxicity were observed in 20.6% and 1.1% of all patients, respectively. Grade 4 non-hematologic toxicity was not observed.

Conclusions

The regimen of paclitaxel, 5-FU and cisplatin demonstrated activity and accepatable toxicity for treating metastatic gastric cancer.

Citations

Citations to this article as recorded by  
  • Intraperitoneal administration of biocompatible hyaluronic acid hydrogel containing multi-chemotherapeutic agents for treatment of colorectal peritoneal carcinomatosis
    Jia Luo, ZhouXue Wu, Yun Lu, Kang Xiong, Qian Wen, Ling Zhao, BiQiong Wang, Yan Gui, ShaoZhi Fu
    International Journal of Biological Macromolecules.2020; 152: 718.     CrossRef
  • A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells
    Gaetano Marverti, Gaia Gozzi, Eleonora Maretti, Angela Lauriola, Leda Severi, Francesca Sacchetti, Lorena Losi, Salvatore Pacifico, Stefania Ferrari, Glauco Ponterini, Eliana Leo, Maria Paola Costi, Domenico D’Arca
    International Journal of Molecular Sciences.2020; 21(12): 4452.     CrossRef
  • Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma
    Cui Chen, Feng-hua Wang, Xin An, Hui-yan Luo, Zhi-qiang Wang, Ying Liang, Le Zhang, Yu-hong Li
    Cancer Chemotherapy and Pharmacology.2013; 71(2): 371.     CrossRef
  • Targeted therapy for gastric cancer—current status
    Jan Kulig, Piotr Kołodziejczyk, Piotr Kulig, Janusz Legutko
    Journal of Oncology Pharmacy Practice.2013; 19(1): 75.     CrossRef
  • Targeted Therapies for Gastric Cancer
    Jaclyn Yoong, Michael Michael, Trevor Leong
    Drugs.2011; 71(11): 1367.     CrossRef
  • Down-Regulation of Human Epidermal Growth Factor Receptor 2/neu Oncogene by Corosolic Acid Induces Cell Cycle Arrest and Apoptosis in NCI-N87 Human Gastric Cancer Cells
    Myung Sun Lee, Eun Young Cha, Phuong Thien Thuong, Ji Yeon Kim, Moon Sang Ahn, Ji Young Sul
    Biological and Pharmaceutical Bulletin.2010; 33(6): 931.     CrossRef
  • Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma
    Hye Ryun Kim, Seong Ha Cheon, Kwang-Hun Lee, Jung Ryun Ahn, Hei-Cheul Jeung, Sung Sook Lee, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha
    International Journal of Hyperthermia.2010; 26(4): 305.     CrossRef
  • 9,651 View
  • 63 Download
  • 7 Crossref
Close layer
A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer
Bong-Gun Seo, Sung Yong Oh, Dong Mee Lee, Hyun Seung Yoo, Suee Lee, Seong-Geun Kim, Sung-Hyun Kim, Hyuk-Chan Kwon, Hyo-Jin Kim
Cancer Res Treat. 2007;39(1):6-9.   Published online March 31, 2007
DOI: https://doi.org/10.4143/crt.2007.39.1.6
AbstractAbstract PDFPubReaderePub
Purpose

To evaluate the therapeutic activity and safety of paclitaxel and cisplatin combination chemotherapy in patients with advanced or metastatic gastric cancers that are unresponsive to primary chemotherapy.

Materials and Methods

Advanced or metastatic gastric cancer patients unresponsive to first line chemotherapy were entered into this trial. The treatment regimen consisted of paclitaxel, 175 mg/m2 by 3-hour infusion on day 1, and cisplatin, 60 mg/m2 by 1 hour infusion on day 1, with the treatment repeated every 3 weeks.

Results

37 patients were entered in this study, with 32 fully evaluable for response. 4 (13%), 13 (40%) and 15 (47%) patients achieved a partial response, stable disease and progressed, respectively. The median time to progression was 4.0 months (95% CI: 2.0~6.0 months), and the median overall survival was 12.6 months (95% CI: 5.5~19.7 months), with a 1-year survival rate of 54%. Of a total of 135 cycles of chemotherapy, grades 3 and 4 hematological toxicities were neutropenia (14%) and anemia (3%). Grade ≥2 neuropathy was observed in 6 patients (17%).

Conclusion

The combination of paclitaxel and cisplatin is an effective and tolerable salvage treatment modality for advanced gastric cancer.

Citations

Citations to this article as recorded by  
  • Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study
    Hieu Trong Nguyen, Kien Hung Do, Nguyen Ba Le, Thang Tran
    Cancer Management and Research.2022; Volume 14: 2825.     CrossRef
  • Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer
    Q. Sun, C. Liu, H. Zhong, B. Zhong, H. Xu, W. Shen, D. Wang
    Japanese Journal of Clinical Oncology.2009; 39(4): 237.     CrossRef
  • 9,226 View
  • 45 Download
  • 2 Crossref
Close layer
A Multi-Center, Phase II Clinical Trial of Padexol™ (Paclitaxel) and Cisplatin for Patients Suffering with Advanced Gastric Cancer
Min Kyoung Kim, Kyung Hee Lee, Myung Soo Hyun, Young Rok Do, Hong Suk Song, Won Sik Lee, Keon Uk Park, Jin Ho Baek, Jong Gwang Kim
Cancer Res Treat. 2005;37(6):349-353.   Published online December 31, 2005
DOI: https://doi.org/10.4143/crt.2005.37.6.349
AbstractAbstract PDFPubReaderePub
Purpose

We conducted a multi-center, phase II trial to evaluate the efficacy and safety of using Padexol (a paclitaxel formulation) combined with cisplatin for the patients suffering with advanced gastric adenocarcinoma.

Materials and Methods

39 patients (median age: 60 years; males: 90%) who were diagnosed with advanced gastric cancer were enrolled from 5 hospitals. Padexol 175 mg/m2 was administered as a 3-hr infusion, and this was followed by cisplatin 75 mg/m2 as an intravenous infusion on day 1, once every 3 weeks.

Results

Out of these 39 patients, 34 patients were assessable for treatment efficacy and 39 patients were assessable for the toxicity. Objective responses occurred in 13 patients (33%); 1 patient (3%) had a complete response and 12 patients (31%) had partial responses. 6 patients (15%) achieved a stable disease state. The median duration of response was 7.1 months, and the median time to progression and the overall survival were 4.8 months and 6.7 months, respectively. The major treatment-related adverse events were hematologic toxicity, including WHO grade 3 or 4 neutropenia in 13 patients (33%). However, febrile neutropenia occurred in only 1 patient and the non-hematologic toxicity was usually mild.

Conclusion

The combination of Padexol and cisplatin was found to be active and it seems to be a relatively well-tolerated regimen for the treatment of advanced gastric cancer.

Citations

Citations to this article as recorded by  
  • Effect of the Weekly Administration of Liposome–Paclitaxel Combined with S-1 on Advanced Gastric Cancer
    Lei Chen, Qiang Chen, Zhixiang Zhuang, Yusong Zhang, Jialong Tao, Liqin Shen, Xudong Shen, Zhigang Chen, Ji Wang, Minggao Zhu, Hui Wang
    Japanese Journal of Clinical Oncology.2014; 44(3): 208.     CrossRef
  • Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer
    Jin Young Kim, Young Rok Do, Keon Uk Park, Jong Gwang Kim, Yee Soo Chae, Min Kyoung Kim, Kyung Hee Lee, Hun Mo Ryoo, Sung Hwa Bae, Jin Ho Baek, Hong Suk Song
    Cancer Chemotherapy and Pharmacology.2011; 67(3): 527.     CrossRef
  • Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer
    Yuji Ueda, Hisakazu Yamagishi, Daisuke Ichikawa, Kazuma Okamoto, Eigo Otsuji, Jun Morii, Kinya Koizumi, Naoki Kakihara, Masataka Shimotsuma, Tetsuro Yamashita, Fumihiro Taniguchi, Hideki Aragane, Hiroshi Nishi, Yoshiki Itokawa, Satoshi Morita, Junichi Sak
    Gastric Cancer.2010; 13(3): 149.     CrossRef
  • TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin
    Jong Gwang Kim, Sang Kyun Sohn, Yee Soo Chae, Hong Suk Song, Ki-Young Kwon, Young Rok Do, Min Kyoung Kim, Kyung Hee Lee, Myung Soo Hyun, Won Sik Lee, Chang-Hak Sohn, Joo Seop Jung, Gab Chul Kim, Ho Young Chung, Wansik Yu
    Cancer Chemotherapy and Pharmacology.2009; 64(2): 355.     CrossRef
  • Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer
    Q. Sun, C. Liu, H. Zhong, B. Zhong, H. Xu, W. Shen, D. Wang
    Japanese Journal of Clinical Oncology.2009; 39(4): 237.     CrossRef
  • A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer
    Bong-Gun Seo, Sung Yong Oh, Dong Mee Lee, Hyun Seung Yoo, Suee Lee, Seong-Geun Kim, Sung-Hyun Kim, Hyuk-Chan Kwon, Hyo-Jin Kim
    Cancer Research and Treatment.2007; 39(1): 6.     CrossRef
  • Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer
    Jong Gwang Kim, Sang Kyun Sohn, Hong Suk Song, Ki-Young Kwon, Young Rok Do, Kyung Hee Lee, Myung Soo Hyun, Hun Mo Ryoo, Sung Hwa Bae, Keon Uk Park, Jin Ho Baek, Won Sik Lee, Joo Seop Chung, Goon Jae Cho, Chang-Hak Sohn, Jung Soon Jang, Ho Young Chung, Wan
    Cancer Chemotherapy and Pharmacology.2007; 60(6): 863.     CrossRef
  • The Efficacy and Safety of Padexol® (Paclitaxel) and Cisplatin for Treating Advanced Non-small Cell Lung Cancer
    Hoon-Kyo Kim, Jun Suk Kim, Hun Mo Ryoo, Dong Gun Shin, Byoung Young Shim, Kyong Hwa Park, Sung Hwa Bae, Chi Hong Kim
    Cancer Research and Treatment.2006; 38(2): 66.     CrossRef
  • 10,251 View
  • 72 Download
  • 8 Crossref
Close layer
Proteome Analysis of Differential Protein Expression in Cervical Cancer Cells after Paclitaxel Treatment
Eun-Kyoung Yim, Jun-Sang Bae, Seung-Bak Lee, Keun-Ho Lee, Chan-Joo Kim, Sung-Eun Namkoong, Soo-Jong Um, Jong-Sup Park
Cancer Res Treat. 2004;36(6):395-399.   Published online December 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.6.395
AbstractAbstract PDFPubReaderePub
Purpose

It is well known that infection with HPV (human papillomavirus) is the main cause of cervical cancer and certain types of HPV are recognized as carcinogens. At present, there is little information regarding the antineoplastic mechanism of paclitaxel against cervical carcinoma cells. We thus tried to analyze differential protein expression and antineoplastic mechanism-related proteins after paclitaxel treatment on cervical cancer cells by using a proteomic analysis and to investigate the mechanism of action.

Materials and Methods

Using proteomics analysis including 2-DE and MALDI-TOF-MS, we detected the antineoplastic mechanism-related proteins. Then, we performed western blot analysis for apoptosis- and transformation-related proteins to confirm expression patterns derived from proteome analysis after paclitaxel treatment.

Results

We identified several cellular proteins that are responsive to paclitaxel treatment in HeLa cells using proteomics methods. Paclitaxel treatment elevated mainly apoptosis, immune response and cell cycle check point-related proteins. On the other hand, paclitaxel treatment diminished growth factor/oncogene-related proteins and transcription regulation-related proteins. Also, in the HPV-associated cervical carcinoma cells, paclitaxel demonstrated anti-proliferative activity through the membrane death receptor-mediated apoptotic pathway and the mitochondrial-mediated pathway.

Conclusion

Identification and characterization of functionally modulated proteins involved in anti-cancer regulatory events should lead to a better understanding of the long-term actions of paclitaxel at the molecular level and will contribute to the future development of novel therapeutic drug treatments based upon current therapies.

Citations

Citations to this article as recorded by  
  • Proteomic Analysis of Thermus thermophilus Cells after Treatment with Antimicrobial Peptide
    Alexey K. Surin, Anna I. Malykhina, Michail V. Slizen, Alexey P. Kochetov, Mariya Yu. Suvorina, Vadim E. Biryulyov, Sergei Y. Grishin, Oxana V. Galzitskaya
    Bacteria.2024; 3(4): 299.     CrossRef
  • Proteomics approaches in cervical cancer: focus on the discovery of biomarkers for diagnosis and drug treatment monitoring
    Georgia Kontostathi, Jerome Zoidakis, Nicholas P. Anagnou, Kalliopi I. Pappa, Antonia Vlahou, Manousos Makridakis
    Expert Review of Proteomics.2016; 13(8): 731.     CrossRef
  • PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer
    Haiyan Zhu, Jun Wu, Wenwen Zhang, Hui Luo, Zhaojun Shen, Huihui Cheng, Xueqiong Zhu
    Scientific Reports.2016;[Epub]     CrossRef
  • Proteomic Analysis of Anticancer TCMs Targeted at Mitochondria
    Yang Wang, Ru-Yuan Yu, Qing-Yu He
    Evidence-Based Complementary and Alternative Medicine.2015; 2015: 1.     CrossRef
  • Mass Spectrometry-Based Proteomics in Molecular Diagnostics: Discovery of Cancer Biomarkers Using Tissue Culture
    Debasish Paul, Avinash Kumar, Akshada Gajbhiye, Manas K. Santra, Rapole Srikanth
    BioMed Research International.2013; 2013: 1.     CrossRef
  • Identification of Cervical Cancer Proteins Associated With Treatment With Paclitaxel and Cisplatin in Patients
    Huiling Liu, Yin Han, Ruoran Mi, Ying Zhang, Gang Su, Hailin Wang, Xin Zhou, Xiangwen Liu, Bingdong Zhu
    International Journal of Gynecological Cancer.2011; 21(8): 1452.     CrossRef
  • Impact of taxol on dermal papilla cells — A proteomics and bioinformatics analysis
    Pei-Hsiu Chen, Chih-Yuan Wang, Ching-Wu Hsia, Ming-Yi Ho, Ann Chen, Min-Jen Tseng, Yung-Fu Wu, Han-Min Chen, Tzu-Hao Huang, Hung-Te Liu, Hao-Ai Shui
    Journal of Proteomics.2011; 74(12): 2760.     CrossRef
  • 10,608 View
  • 64 Download
  • 7 Crossref
Close layer
A Phase II Study of Weekly Paclitaxel, Cisplatin and Concurrent Radiation Therapy for Locally-Advanced Unresectable Non-Small Cell Lung Cancer: Early Closure due to Lack of Efficacy
Se Hoon Park, Mi Kyung Kim, Sun Young Kyung, Young-Hee Lim, Chang Hyeok An, Jeong Woong Park, Seong Hwan Jeong, Jae Woong Lee, Kyu Chan Lee, Eun Kyung Cho, Soo Mee Bang, Dong Bok Shin, Jae Hoon Lee
Cancer Res Treat. 2004;36(5):293-297.   Published online October 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.5.293
AbstractAbstract PDFPubReaderePub
Purpose

In this phase II study, the efficacy and safety of weekly paclitaxel concomitant with cisplatin and thoracic radiotherapy (TRT) was evaluated in patients with locally-advanced unresectable non-small cell lung cancer (NSCLC).

Materials and Methods

Patients with stage III NSCLC (without pleural effusion or cervical lymphadenopathy) received TRT (63 Gy in 35 fractions over 7 weeks) with concurrent weekly cisplatin 20 mg/m2 and paclitaxel 40 mg/m2/week infused over 3 hours. In patients without evidence of disease progression, the administration of a further 2 cycles of consolidation chemotherapy, consisting of paclitaxel 175 mg/m2 and cisplatin 75 mg/m2, were planned after completion of the TRT.

Results

Between Feb 2000 and Dec 2002, 20 patients were entered into the study; 13 completed all 7 weeks of treatment (median 7.6 weeks; range 3.3 to 9.4). Seven out of 16 (43.8%) objective responses were observed, with 15 (75%) patients experiencing at least one episode of grade 3/4 toxicity. The main toxicities were moderate to severe neutropenia and gastrointestinal toxicity.

Conclusion

The unsatisfactory response rate and the high incidence of grade 3/4 hematologic and non-hematologic toxicities, including 7 early discontinuations of treatment and exceeding the study stopping rules, prompted the early closure of the study. In view of the activity observed, the protocol was amended to protracted continuous infusion paclitaxel, cisplatin and concurrent TRT.

  • 8,461 View
  • 53 Download
Close layer
Paclitaxel and Cisplatin Combination Chemotherapy in Pretreated Breast Cancer
Joo Hyuk Sohn, Yong Tai Kim, Sun Young Rha, Nae Choon Yoo, Jae Kyung Roh, Byung Soo Kim, Chang Ok Suh, Gwi Eon Kim, Woo Ick Jang, Hyun Cheol Chung
Cancer Res Treat. 2003;35(3):267-273.   Published online June 30, 2003
DOI: https://doi.org/10.4143/crt.2003.35.3.267
AbstractAbstract PDF
PURPOSE
A single institute trial of combination chemotherapy, with paclitaxel and cisplatin, in patients with metastatic breast cancer, having failed previous combination chemotherapy, was performed. MATERIALS AND METHODS: Patients were only eligible for this study if there disease had progressed, following treatment with previous chemotherapy, in either an adjuvant or a metastatic setting. Paclitaxel 175 mg/m2 was administered as a 3-hour continuous infusion on day 1, and cisplatin 80 mg/m2 was administered for 2 hours on day 2, with adequate hydration. This was repeated every 3 weeks, and continued until one of the following events occurred: disease progression, unacceptable adverse effect or treatment refusal by the patient. Intercurrent palliative radiotherapy, or concurrent hormonal therapy, was permitted, depending on each patient's status. All the endpoints were evaluated under the principle of intention to treat analysis. RESULTS: A total of 24 patients entered the study, and 18 had at least one measurable lesion, but 6 did not. The objective response rate of the 18 patients was 50%(9/18). Two were complete responses and seven showed partial responses. The median response duration, progression free and overall survival were 5.3 months (range, 4~18), 6 months (95% CI, 5~7) and 12 months (95% CI, 7~17), respectively. 67% of the planned dose was administered. Out of a total 135 cycles administered, about 20% of cycles showed grade 3 or 4 leukopenia and 7% showed grade 3 thrombocytopenia. Two patients suffered from pneumonia, and one experienced neutropenic fever. Mucositis, greater than grade 3, existed in three cases. No treatment related deaths were reported. CONCLUSION: The combination chemotherapy, with paclitaxel and cisplatin, was active in the treatment of metastatic breast cancer patients having failed previous chemotherapy.

Citations

Citations to this article as recorded by  
  • Cisplatin in Ovarian Cancer Treatment—Known Limitations in Therapy Force New Solutions
    Aleksandra Zoń, Ilona Bednarek
    International Journal of Molecular Sciences.2023; 24(8): 7585.     CrossRef
  • Fever and breast cancer: A critical review of the literature and possible underlying mechanisms
    Shiva Mehran, Afshin Taravati, Esfandiar Baljani, Yousef Rasmi, Zafar Gholinejad
    Breast Disease.2021; 40(3): 117.     CrossRef
  • 3D Collagen Vascular Tumor-on-a-Chip Mimetics for Dynamic Combinatorial Drug Screening
    Li Wan, Jun Yin, John Skoko, Russell Schwartz, Mei Zhang, Philip R. LeDuc, Carola A. Neumann
    Molecular Cancer Therapeutics.2021; 20(6): 1210.     CrossRef
  • A New and Integral Approach to the Etiopathogenesis and Treatment of Breast Cancer Based upon Its Hydrogen Ion Dynamics
    Salvador Harguindey, Khalid Alfarouk, Julián Polo Orozco, Kévin Hardonnière, Daniel Stanciu, Stefano Fais, Jesús Devesa
    International Journal of Molecular Sciences.2020; 21(3): 1110.     CrossRef
  • Towards an Integral Therapeutic Protocol for Breast Cancer Based upon the New H+-Centered Anticancer Paradigm of the Late Post-Warburg Era
    Salvador Harguindey, Khalid Alfarouk, Julián Polo Orozco, Stefano Fais, Jesús Devesa
    International Journal of Molecular Sciences.2020; 21(20): 7475.     CrossRef
  • 4,860 View
  • 59 Download
  • 5 Crossref
Close layer
A Phase II Study of Paclitaxel and Cisplatin Combination Chemotherapy in Advanced Non-small-cell Lung Cancer
Jung Ae Lee, Keun Seok Lee, Jin Seok Ahn, Jae Ho Byun, Hun Ho Song, Dae Young Zang, Young Iee Park, Young Suk Park, Eun Kyung Mo, Dong Kyu Kim, Myung Goo Lee, In Gyu Hyun, Ki Suck Jung, Soo Mee Bang, Gye Young Park, Jeong Woong Park, Eun Kyung Cho, Seong Hwan Jeong, Dong Bok Shin, Jae Hoon Lee
Cancer Res Treat. 2003;35(3):239-244.   Published online June 30, 2003
DOI: https://doi.org/10.4143/crt.2003.35.3.239
AbstractAbstract PDF
PURPOSE
Paclitaxel and cisplatin, active drugs in the treatment of non-small-cell lung cancer (NSCLC), have been found to be synergistic and less myelotoxic in combination when the paclitaxel is given 24 hr prior to the cisplatin. Their antitumor activity and toxicity in patients with advanced NSCLC has been evaluated herein. MATERIALS AND METHODS: Seventy-four chemonaive patients, with advanced NSCLC, were enrolled. Paclitaxel, 175 mg/m2, was administered on day 1, followed 24 hr later by cisplatin, 75 mg/m2, on day 2. RESULTS: The overall response rate, median time to progression and median survival time were 51%, 7.1 months (95% confidence interval (CI), 5.5~8.7 months) and 13.7 months (95% CI, 11.3~16.1 months), respectively. There were significant differences in the overall survival rates in relation to stage and the ECOG performance status(PS). The toxicity was mainly nonhematological. Grade > or =3 neuropathy occurred in 2 (3%) patients, myalgia in 3 (4%), and bone pain in 3 (4%). The hematological toxicity was mild, and no grade 3 or 4 neutropenia was observed.
CONCLUSION
The combination of paclitaxel and cisplatin is an effective and tolerable treatment regimen for advanced NSCLC during first line chemotherapy. The main toxicity was nonhematological, such as peripheral neuropathy, myalgia and bone pain, whereas the hematological toxicity itself was mild.

Citations

Citations to this article as recorded by  
  • The Efficacy and Safety of Padexol® (Paclitaxel) and Cisplatin for Treating Advanced Non-small Cell Lung Cancer
    Hoon-Kyo Kim, Jun Suk Kim, Hun Mo Ryoo, Dong Gun Shin, Byoung Young Shim, Kyong Hwa Park, Sung Hwa Bae, Chi Hong Kim
    Cancer Research and Treatment.2006; 38(2): 66.     CrossRef
  • 4,879 View
  • 32 Download
  • 1 Crossref
Close layer
A Multi-Center, Phase II Clinical Trial of Genexol(R) (Paclitaxel) and Cisplatin for Patients with Non-Small Cell Lung Cancer
Se Hoon Lee, Keunchil Park, Cheolwon Suh, Hoon Kyo Kim, Jun Suk Kim, Young Hyuck Im, Sang We Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim
Cancer Res Treat. 2003;35(1):30-34.   Published online February 28, 2003
DOI: https://doi.org/10.4143/crt.2003.35.1.30
AbstractAbstract PDF
PURPOSE
A combination of paclitaxel and cisplatin is an effective and safe regimen for advanced non-small cell lung cancer (NSCLC). We conducted a multi-center, phase II trial to evaluate the efficacy and safety of Genexol(R) (paclitaxel) and cisplatin in patients with NSCLC. MATERIALS AND METHODS: Chemotherapy-na ve patients having histologically confirmed NSCLC were enrolled. Genexol(R) was administered at 175 mg/m2 as a 3-hour intravenous infusion and cisplatin at 75 mg/m2 as an intravenous infusion on day 1 every 3 weeks. RESULTS: Twenty-five of 27 patients that were entered from 5 hospitals between Jan 2001 and Aug 2001 received chemotherapy. On an intent-to-treat basis, 9 patients (36%) achieved a partial response, 7 patients (28%) a stable disease, and 5 patients (20%) The overall response rate was 36% (95% CI, 17 to 55%). progressed. The median duration of the response was 7.8 months (95% CI, 6.6 to 9.0 months). The median time to progression was 7.4 months (95% CI, 5.3 to 9.5 months), and median overall survival was 13.3 months (95% CI, 10.8 to 15.9 months) for the intent-to-treat population. The major oxicity was hematological, with grade 3 and 4 neutropenia in 10% (10/106) of the total cycles. The non-hematologic oxicity was mild, and grade 3 emesis was observed in 2 patients (8%). One patient experienced a moderate degree hypersensitivity reaction. CONCLUSION: The results suggest that a combination of Genexol(R) and cisplatin is an effective and well-tolerated regimen for patients with NSCLC.

Citations

Citations to this article as recorded by  
  • Phase II Clinical Trial of Genexol(R) (Paclitaxel) and Carboplatin for Patients with Advanced Non-small Cell Lung Cancer
    Han Jo Kim, Kyoung Ha Kim, Jina Yun, Se Hyung Kim, Hyun Jung Kim, Sang-Cheol Lee, Sang Byung Bae, Chan Kyu Kim, Nam Su Lee, Kyu Taek Lee, Do-Jin Kim, Seong-Kyu Park, Jong-Ho Won, Dae Sik Hong, Hee Sook Park
    Cancer Research and Treatment.2011; 43(1): 19.     CrossRef
  • Minimizing tumor burden by extensive cytoreductive surgery decreases postoperative venous thromboembolism in ovarian clear cell carcinoma
    Myong Cheol Lim, Hee Seok Lee, Sokbom Kang, Sang-Soo Seo, Bo Yon Lee, Sang-Yoon Park
    Archives of Gynecology and Obstetrics.2010; 281(2): 329.     CrossRef
  • Pathological Diagnosis and Cytoreduction of Cardiophrenic Lymph Node and Pleural Metastasis in Ovarian Cancer Patients Using Video-Assisted Thoracic Surgery
    Myong Cheol Lim, Hyun-Sung Lee, Dae Chul Jung, Ji Young Choi, Sang-Soo Seo, Sang-Yoon Park
    Annals of Surgical Oncology.2009; 16(7): 1990.     CrossRef
  • The Efficacy and Safety of Padexol® (Paclitaxel) and Cisplatin for Treating Advanced Non-small Cell Lung Cancer
    Hoon-Kyo Kim, Jun Suk Kim, Hun Mo Ryoo, Dong Gun Shin, Byoung Young Shim, Kyong Hwa Park, Sung Hwa Bae, Chi Hong Kim
    Cancer Research and Treatment.2006; 38(2): 66.     CrossRef
  • 4,001 View
  • 34 Download
  • 4 Crossref
Close layer
Antitumor Activity of Oxaliplatin, 5-FU and Paclitaxel Given Alone or in Combination with ZD1839 in Human Gastric Carcinoma Cells in vitro
Ji Hyun Jang, Sang Hak Lee, Jin Hyoung Kang, Hee Sik Sun, Kazuto Nishio, Nagahiro Saijo, Hyo Jeong Kuh
Cancer Res Treat. 2002;34(5):372-381.   Published online October 31, 2002
DOI: https://doi.org/10.4143/crt.2002.34.5.372
AbstractAbstract PDF
PURPOSE
Oxaliplatin (LOHP), 5-FU, and paclitaxel (PTX) are considered highly active against advanced gastric carcinomas, and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, ZD1839 is considered as a good candidate for the treatment of gastric cancers when given alone or in combination with cytotoxic agents. The present study evaluated the antitumor effects of these agents in SNU-1 human gastric cancer cells either alone or when given as a doublet (i.e., as a cytotoxic-cytostatic combination).
MATERIALS AND METHODS
We selected SNU-1 cells that showed DNA mismatch repair (MMR) deficiency and EGFR overexpression. Growth inhibition was measured by MTT and by direct cell counting and cell cycle distribution by flow cytometry. The combination index (CI) was used to describe synergistic interaction.
RESULTS
The four drugs showed IC50s ranging from 1.81 nM to 13.2microM. MTT assay appeared to underestimate the cytotoxicity of PTX, which was attributed to a significant resistant fraction (32%). LOHP and PTX induced G2/M arrest, 5-FU increased in S phase, and ZD1839 in-creased in G1 in a concentration dependent manner. PTX ZD1839 showed the greatest synergism and LOHP ZD1839 showed a similar result. The cell cycle effect of PTX was potentiated by the coadministration of ZD1839. A previously developed cytostatic TPi model was used to assess the contribution of cell cycle arrest to overall growth inhibition, and 64% and 80% of the overall growth inhibition was attributed to cell cycle arrest for LOHP and PTX, when exposed to 7.55microM and 10 nM for 72 hr, respectively.
CONCLUSION
This study demonstrates the antitumor activity and significant cell cycle arrest effect of ZD1839 against human gastric carcinoma cells and its synergistic interaction with LOHP and PTX. These results provide a preclinical rationale for the clinical development of ZD1839 and its use in combination with LOHP or PTX against human gastric cancers that express EGFR.

Citations

Citations to this article as recorded by  
  • Connecting Agent-Based Models with High-Dimensional Parameter Spaces to Multidimensional Data Using SMoRe ParS: A Surrogate Modeling Approach
    Daniel R. Bergman, Kerri-Ann Norton, Harsh Vardhan Jain, Trachette Jackson
    Bulletin of Mathematical Biology.2024;[Epub]     CrossRef
  • A confidence building exercise in data and identifiability: Modeling cancer chemotherapy as a case study
    Marisa C. Eisenberg, Harsh V. Jain
    Journal of Theoretical Biology.2017; 431: 63.     CrossRef
  • 4,961 View
  • 37 Download
  • 2 Crossref
Close layer
Efficacy of Combination Chemotherapy with Paclitaxel and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer
Eun Jung Rhee, Hyun Sik Jeong, Seung Sei Lee
Cancer Res Treat. 2002;34(1):28-33.   Published online February 28, 2002
DOI: https://doi.org/10.4143/crt.2002.34.1.28
AbstractAbstract PDF
PURPOSE
To evaluate the efficacy and toxicity of the combination therapy of paclitaxel and cisplatin in advanced, non-small cell, lung cancer patients MATERIALS AND METHODS: Between December 1997 and September 2001, 37 patients with advanced, non-small cell, lung cancer were enrolled in this study. Patients were treated with paclitaxel (135 mg/m2, 24 hr infusion) and cisplatin (75 mg/m2). The treatments were repeated every 4 weeks.
RESULTS
Among the 37 patients enrolled, 21 were treated with paclitaxel and cisplatin as a first-line and 16 patients as a second-line. The median age of the patients was 59. In the first-line group, 10 had stage IIIB and 11 had stage IV, non small cell lung cancer. Of 21 patients in first-line treatment group that could be evaluated, objective responses were observed in 6 patients (response rate: 28.6%, CR: 4.8%, PR: 23.8%). The mediansurvival duration for patients was 48 weeks. With the second-line group, 3 patients showed a partial response (response rate: 18.7%) to treatment, with median survival duration of 44 weeks. Grade 3-4 leukopenia was observed in 27.1% of the first-line, and 23.6% in second- line, treatment groups.
CONCLUSION
Combination chemotherapy, with paclitaxel and cisplatin, in non-small cell lung cancer has acceptable toxicities in both first and second-line treatment groups. In terms of efficacy, no superior response was shown for either group. More randomized studies, with a larger group of patients, are required to prove the true efficacy.

Citations

Citations to this article as recorded by  
  • Co-delivery of paclitaxel and cisplatin in poly(2-oxazoline) polymeric micelles: Implications for drug loading, release, pharmacokinetics and outcome of ovarian and breast cancer treatments
    Xiaomeng Wan, James J. Beaudoin, Natasha Vinod, Yuanzeng Min, Naoki Makita, Herdis Bludau, Rainer Jordan, Andrew Wang, Marina Sokolsky, Alexander V. Kabanov
    Biomaterials.2019; 192: 1.     CrossRef
  • Proximal Gastrectomy Reconstructed by Jejunal Pouch Interposition for Upper Third Gastric Cancer: Prospective Randomized Study
    Chang Hak Yoo, Byung Ho Sohn, Won Kon Han, Won Kil Pae
    World Journal of Surgery.2005; 29(12): 1592.     CrossRef
  • Long-term Results of Proximal and Total Gastrectomy for Adenocarcinoma of the Upper Third of the Stomach
    Chang Hak Yoo, Byung Ho Sohn, Won Kon Han, Won Kil Pae
    Cancer Research and Treatment.2004; 36(1): 50.     CrossRef
  • 4,130 View
  • 44 Download
  • 3 Crossref
Close layer
Efficacy of Low-dose Paclitaxel and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer
Byung Su Kim, Do Youn Oh, Yo Han Joh, Do Yeun Kim, Jee Hyun Kim, Se Hoon Lee, Dae Ho Lee, Tae You Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim
Cancer Res Treat. 2001;33(6):469-473.   Published online December 31, 2001
DOI: https://doi.org/10.4143/crt.2001.33.6.469
AbstractAbstract PDF
PURPOSE
To evaluate the efficacy and toxicity of combination chemotherapy with low-dose paclitaxel and cisplatin in patients with advanced non-small cell lung cancer.
MATERIALS AND METHODS
Chemotherapy-naive patients with unresectable, pathologically proven non-small cell lung cancer were eligible for inclusion in the study. Patients received paclitaxel (145 mg/m2 iv 3 hour D1) and cisplatin (60 mg/m2 iv D1) every 3 weeks.
RESULTS
Forty-two patients were enrolled between February 2000 and February 2001. The median age was 53.5 years. Patients with adenocarcinoma numbered 29, squamous cell carcinoma 7, large cell carcinoma 3, and undifferentiated carcinoma 3. Seventeen patients had stage IIIB, 19 had stage IV disease and the remaining 6 displayed recurred disease after previous surgical resection. Four patients terminated treatment early because of hypersensitivity (1) and severe emesis (3). Of the 38 evaluable patients, 14 had PR and the response rate was 36.8%. Among partial responders, 6 patients received additional chest radiation. The median duration of response was 47.9 weeks and the median overall survival was 54.0 weeks. Of the total 176 courses, 14 were delayed, 22 required dose reduction, and grade 3~4 neutropenia occurred in 5.6% of courses. Only one episode of neutropenic fever developed and there were no treatment- related mortalities. Other toxicities were generally mild.
CONCLUSION
The combination chemotherapy with low-dose paclitaxel and cisplatin was effective and tolerable in patients with advanced non-small cell lung cancer.

Citations

Citations to this article as recorded by  
  • Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer
    Keun-Wook Lee, Jee Hyun Kim, Tak Yun, Eun Kee Song, Im il Na, Hyunchoon Shin, So Yeon Oh, In Sil Choi, Do-Youn Oh, Dong-Wan Kim, Seock-Ah Im, Tae-You Kim, Jong Seok Lee, Dae Seog Heo, Yung-Jue Bang, Noe Kyeong Kim
    Journal of Korean Medical Science.2007; 22(Suppl): S115.     CrossRef
  • Phase II Trial of Low-dose Paclitaxel and Cisplatin in Patients with Advanced Gastric Cancer
    Keun-Wook Lee, Seock-Ah Im, Tak Yun, Eun Kee Song, Im il Na, Hyunchoon Shin, In Sil Choi, Do-Youn Oh, Jee Hyun Kim, Dong-Wan Kim, Tae-You Kim, Jong Seok Lee, Dae Seog Heo, Yung-Jue Bang, Noe Kyeong Kim
    Japanese Journal of Clinical Oncology.2005; 35(12): 720.     CrossRef
  • 4,366 View
  • 27 Download
  • 2 Crossref
Close layer
Phase I Clinical Trial of Paclitaxel Plus Ifosfamide for the Patients with Refractory Ovarian Cancer
Ho Sawk Saw, Jae Kwan Lee
J Korean Cancer Assoc. 2000;32(5):895-903.
AbstractAbstract PDF
PURPOSE
Patients with advanced ovarian carcinoma and refractory to platinum based chemotherapy have a very poor prognosis and effective salvage regimens are needed. This study was conducted in order to determine the maximum tolerated dose (MTD) and dose limiting toxicity of combination with paclitaxel and ifosfamide.
MATERIALS AND METHODS
After premedication, patients received paclitaxel (110~225 mg/m2) as a 24 hour IV infusion on day 1. Ifosfamide (1,000~1,500 mg/m2) was given as a 12 hour IV infusion with standard dose of mesna on day 2~6. All patients received G-CSF (granulocyte colony stimulating factor) on day 6~15.
RESULTS
12 patients with advanced ovarian cancer entered this trial. Toxicity included bone marrow suppression, neuromuscular toxicity, urothelial toxicity, gastrointestinal toxicity, which occurred in 84.6%, 65.3%, 30.7%, 88.4% of cycles.
CONCLUSION
Neuromuscular toxicity was dose limiting toxicity. Maximum tolerated dose in com bination with paclitaxel and ifosfamide was 175 mg/m2 of paclitaxel and 1,500 mg/m2 of ifosfamide.
  • 2,117 View
  • 17 Download
Close layer
Phase II Multicenter Trial of Paclitaxel for Metastatic Breast Cancer
Jae Ho Byun, Sung Soo Yoon, Chan Hyung Park, Sung Rok Kim, Si Young Kim, Hyo Jin Kim, Soo Mee Bang, Heung Moon Chang, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim
J Korean Cancer Assoc. 2000;32(3):545-552.
AbstractAbstract PDF
PURPOSE
To evaluate the efficacy and safety of paclitaxel for metastatic breast cancer patients who had received previous chemotherapy, we have performed phase II multicenter trial between December 1997 and December 1998.
MATERIALS AND METHOD
Thirty patients were accrued to this study and paclitaxel was administered at 175 mg/m2 as a 3-hour intravenous infusion every 3 weeks until the progression of the disease.
RESULTS
Objective response were observed in 13 of 30 patients (43.3%). There were 1 complete response (3.3%) and 12 partial responses (40%). Especially, 50% (11/22) of patients who had received prior anthracycline-containing regimens for adjuvant or metastatic disease responded to paclitaxel. Responses were observed in all sites of metastatic disease. One hundred forty-nine cycles of treatment were administered, with a median of six cycles per patient. Grade III and IV toxicities included neutropenia (24%), elevated liver enzyme (10%), peripheral neuropathy (10%), arthralgia/myalgia (23%), and alopecia (87%). No significant hypersensitivity type reaction or cardiac arrhythmia were seen. Median duration of response was 7.2 months.
CONCLUSIONS
These results suggested that paclitaxel is active therapeutic agent in metastatic breast cancer patients and it can be safely administered by 3-hour intravenous infusion with premedication.
  • 2,932 View
  • 37 Download
Close layer
Effect of Paclitaxol, Cisplatin, and 5-Flurouracil Chemotherapy in Advanced Stomach Cancer
Yeul Hong Kim, Sang Won Shin, Byung Soo Kim, Jin Ho Kim, Jong Kuk Kim, Young Jae Mok, Jong Suk Kim, Chi Wook Song, Ho Sang Ryu, Jun Suk Kim, Jin Hai Hyun
J Korean Cancer Assoc. 1997;29(4):648-655.
AbstractAbstract PDF
PURPOSE
Paclitaxel has not been used widely in gastrointestinal cancers. However, a recent phase II report of paclitaxel in patients with esophageal adenocarcinoma has suggested a possible role of paclitaxel for the treatment of advanced gastric carcinoma. A phase II trial was initiated to determine the clinical utility of a 3 drug combination (paclitaxel, cisplatin, and 5-fluorouracil) in patients with advanced gastric carcinoma.
MATERIALS AND METHODS
Eligibility included biopsy-proven inoperable or relapsed adenocarcinoma of the stomach with adequate bone marrow, hepatic, and renal function. Patients received paclitaxel at 175 mg/m2 (3 hour infusion) on day 1 followed by cisplatin at 20 mg/m2/day infusion and 5-fluorouracil at 750 mg/m2/day continuous infusion for 5 days. Treatment has been repeated in every 4 weeks. Total 31 patients were enrolled; 7 had relapsed disease after resection and 5-fluorouracil based adjuvant chemotherapy, 5 had previous chemotherapy. Twenty-one patients had measurable disease and 9 were evaluable. Demographics included; median age, 47 years (range, 27~64 years); male: female, 21: 10; median performance status 2 (range, 0~4).
RESULTS
Major responses occurred in 16/30 (53%; 95% confidence interval, 35~71%) patients (2 complete responses, 14 partial responses); 13 of 21 (61.9%) patients with measurable disease and 3 of 9 (33%) evaluable patients. Median response duration was 17 weeks (range, 8~44+ weeks) and median time to progression was 20 weeks (range, 8~51+ weeks). Median survival was 27 weeks (range, 8~72+ weeks). WHO grade 3~4 toxicities included: neutropenia (61.9%), nausea/vomiting (23.8%), mucositis (19%), and diarrhea (9.5%). Grade 2~3 neurotoxicity, fluid retention syndrome, hypersensitive reaction had occurred in 6, 2, and 1 patients, respectively. There was 1 instance of treatment-related death due to sepsis.
CONCLUSION
This regimen was highly active in advanced gastric carcinoma and had moderate toxicity. However, the response duration was short like other regimens. Considering poor performance status of our patients, this regimen may have strong potential in the neoadjuvant setting.
  • 3,315 View
  • 13 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP